20 December 2019 EMA/CHMP/653549/2019 Inspections, Human Medicines Pharmacovigilance and Committees Division
Committee for medicinal products for human use (CHMP) Final Minutes for the meeting on 14-17 October 2019 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Disclaimers
Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.
Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.
Note on access to documents
Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Introduction 8 1.1. Welcome and declarations of interest of members, alternates and experts ...... 8 1.2. Adoption of agenda ...... 8 1.3. Adoption of the minutes ...... 8
2. Oral Explanations 8 2.1. Pre-authorisation procedure oral explanations ...... 8 2.1.1. fostamatinib - EMEA/H/C/005012 ...... 9 2.1.2. ciprofloxacin - EMEA/H/C/004394 ...... 9 2.1.3. solriamfetol - EMEA/H/C/004893 ...... 9 2.2. Re-examination procedure oral explanations ...... 9 2.2.1. Evenity - romosozumab - EMEA/H/C/004465 ...... 9 2.3. Post-authorisation procedure oral explanations ...... 10 2.3.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0012 ...... 10 2.3.2. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049 ...... 10 2.3.3. Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0047 ...... 11 2.4. Referral procedure oral explanations ...... 11
3. Initial applications 11 3.1. Initial applications; Opinions ...... 11 3.1.1. BAQSIMI - glucagon - EMEA/H/C/003848 ...... 11 3.1.2. Ervebo - recombinant vesicular stomatitis virus - zaire ebolavirus vaccine (live) - EMEA/H/C/004554 ...... 12 3.1.3. Hopveus - sodium oxybate - EMEA/H/C/004962 ...... 12 3.1.4. Pegfilgrastim Mundipharma - pegfilgrastim - EMEA/H/C/005312 ...... 13 3.1.5. Quofenix - delafloxacin - EMEA/H/C/004860 ...... 13 3.1.6. Rinvoq - upadacitinib - EMEA/H/C/004760 ...... 13 3.1.7. Spravato - esketamine - EMEA/H/C/004535 ...... 14 3.1.8. VANFLYTA - quizartinib - Orphan - EMEA/H/C/004468 ...... 14 3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ...... 15 3.2.1. adalimumab - EMEA/H/C/004879 ...... 15 3.2.2. azacitidine - EMEA/H/C/005147 ...... 15 3.2.3. azacitidine - EMEA/H/C/005075 ...... 15 3.2.4. brolucizumab - EMEA/H/C/004913 ...... 16 3.2.5. cinacalcet - EMEA/H/C/005236 ...... 16 3.2.6. osilodrostat - Orphan - EMEA/H/C/004821 ...... 16 3.2.7. imipenem / cilastatin / relebactam - EMEA/H/C/004808 ...... 16 3.2.8. entrectinib - EMEA/H/C/004936 ...... 17
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 2/56
3.2.9. cholera vaccine, oral, live - EMEA/H/C/003876 ...... 17 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) ...... 17 3.3.1. apixaban - EMEA/H/C/005358 ...... 17 3.3.2. crizanlizumab - Orphan - EMEA/H/C/004874 ...... 17 3.3.3. dasatinib - EMEA/H/C/005446 ...... 18 3.3.4. dasatinib - EMEA/H/C/005317 ...... 18 3.3.5. bupivacaine - EMEA/H/C/004586 ...... 18 3.3.6. givosiran - Orphan - EMEA/H/C/004775 ...... 18 3.3.7. budesonide / formoterol fumarate dihydrate - EMEA/H/C/004882 ...... 19 3.3.8. insulin aspart - EMEA/H/C/005033 ...... 19 3.3.9. obiltoxaximab - Orphan - EMEA/H/C/005169...... 19 3.3.10. doxorubicin - EMEA/H/C/005320 ...... 19 3.3.11. idebenone - Orphan - EMEA/H/C/005123 ...... 19 3.3.12. lefamulin - EMEA/H/C/005048 ...... 20 3.3.13. trastuzumab - EMEA/H/C/005209 ...... 20 3.4. Update on on-going initial applications for Centralised procedure ...... 20 3.4.1. pretomanid - Orphan - EMEA/H/C/005167 ...... 20 3.4.2. selinexor - Orphan - EMEA/H/C/005127 ...... 20 3.4.3. bupivacaine / meloxicam - EMEA/H/C/005205 ...... 21 3.4.4. viable T-cells - Orphan - ATMP - EMEA/H/C/002397 ...... 21 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 ...... 21 3.5.1. Evenity - romosozumab - EMEA/H/C/004465 ...... 21 3.6. Initial applications in the decision-making phase ...... 22 3.7. Withdrawals of initial marketing authorisation application ...... 22 3.7.1. diclofenamide - Orphan - EMEA/H/C/005141 ...... 22 3.7.2. omadacycline - EMEA/H/C/004715 ...... 22
4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 23 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion ...... 23 4.1.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0075/G ...... 23 4.1.2. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0012 ...... 23 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues ...... 24 4.2.1. Dificlir - fidaxomicin - EMEA/H/C/002087/X/0034/G ...... 24 4.2.2. Emgality - galcanezumab - EMEA/H/C/004648/X/0004 ...... 24 4.2.3. Vyndaqel - tafamidis - Orphan - EMEA/H/C/002294/X/0049/G ...... 25
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 3/56
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of questions ...... 25 4.3.1. Harvoni - ledipasvir / sofosbuvir - EMEA/H/C/003850/X/0081/G ...... 25 4.3.2. Sovaldi - sofosbuvir - EMEA/H/C/002798/X/0059/G ...... 26 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 ...... 26 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 ...... 26
5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 26 5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information ...... 26 5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070 ...... 26 5.1.2. Carmustine Obvius - carmustine - EMEA/H/C/004326/II/0002 ...... 27 5.1.3. Cyramza - ramucirumab - EMEA/H/C/002829/II/0033 ...... 27 5.1.4. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0029 ...... 27 5.1.5. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0030 ...... 28 5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0065 ...... 28 5.1.7. Lynparza - olaparib - EMEA/H/C/003726/II/0033 ...... 29 5.1.8. MabThera - rituximab - EMEA/H/C/000165/II/0162 ...... 29 5.1.9. Otezla - apremilast - EMEA/H/C/003746/II/0029 ...... 30 5.1.10. Rezolsta - darunavir / cobicistat - EMEA/H/C/002819/II/0033 ...... 30 5.1.11. SIRTURO - bedaquiline - Orphan - EMEA/H/C/002614/II/0033/G ...... 31 5.1.12. Stelara - ustekinumab - EMEA/H/C/000958/II/0073 ...... 31 5.1.13. Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0011 ...... 31 5.1.14. Toujeo - insulin glargine - EMEA/H/C/000309/II/0108 ...... 32 5.1.15. Tybost - cobicistat - EMEA/H/C/002572/II/0051 ...... 32 5.1.16. Venclyxto - venetoclax - EMEA/H/C/004106/II/0023/G ...... 33 5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G ...... 33 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ...... 34 5.2.1. Axumin - fluciclovine (18F) - EMEA/H/C/004197/II/0011 ...... 34 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ...... 34 5.3.1. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049 ...... 34 5.3.2. Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0047 ...... 35
6. Ancillary medicinal substances in medical devices 35 6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions ...... 35
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 4/56
6.2. Update of Ancillary medicinal substances in medical devices ...... 36
7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 36 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)36
8. Pre-submission issues 36 8.1. Pre-submission issue ...... 36 8.1.1. autologous CD34+ enriched cell fraction that contains CD34+ cells genetically modified ex vivo using a lentiviral vector encoding for the human arylsulfatase A(ARSA) cDNA sequence - Orphan - ATMP - H0005321 ...... 36 8.1.2. valoctocogene roxaparvovec - ATMP - H0004749 ...... 36 8.1.3. ICOSAPENT ETHYL - H0005398 ...... 36 8.1.4. Baloxavir marboxil - H0004974 ...... 37 8.2. Priority Medicines (PRIME) ...... 37 8.2.1. List of applications received ...... 37 8.2.2. Recommendation for PRIME eligibility ...... 37
9. Post-authorisation issues 37 9.1. Post-authorisation issues ...... 37 9.1.1. OCALIVA - obeticholic acid – Orphan - EMEA/H/C/004093/R/0018 ...... 37 9.1.2. Zalmoxis - nalotimagene carmaleucel – Orphan, ATMP - EMEA/H/C/002801 ...... 38 9.1.3. WS1636/G Mekinist-EMEA/H/C/002643/WS1636/0035/G Tafinlar-EMEA/H/C/002604/WS1636/0040/G ...... 38 9.1.4. WS1683 Elebrato Ellipta-EMEA/H/C/004781/ WS1683/0012 Temybric Ellipta-EMEA/H/C/005254/ WS1683/0001 Trelegy Ellipta-EMEA/H/C/004363/ WS1683/001038 9.1.5. Zynteglo - autologous cd34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene - EMEA/H/C/003691/II/0001/G, Orphan, ATMP...... 39 9.1.6. Infanrix hexa – PAM – EMEA/H/C/000296 ...... 39
10. Referral procedures 39 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 ...... 39 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 . 39 10.2.1. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490 ...... 39 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 ...... 40 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC ...... 40 10.4.1. Flurbiprofen Geiser – oromucosal spray – EMEA/H/A-29(4)/1487...... 40 10.4.2. Budesonide SUN – budesonide – EMEA/H/A-29(4)/1492 ...... 41 10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC .... 41 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC ...... 41
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 5/56
10.6.1. Gadolinium-containing contrast agents (GdCA): Gadobutrol (NAP); gadodiamide (NAP); gadopentetic acid (NAP); gadoteric acid (NAP); gadoteridol (NAP); gadoxetic acid (NAP) - EMEA/H/A-31/1097 ...... 41 10.6.2. Methocarbamol/Paracetamol– EMEA/H/A-31/1484 ...... 42 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC ...... 42 10.8. Procedure under Article 107(2) of Directive 2001/83/EC ...... 42 10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 ...... 42 10.10. Procedure under Article 29 of Regulation (EC) 1901/2006...... 42 10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 ...... 42
11. Pharmacovigilance issue 43 11.1. Early Notification System ...... 43
12. Inspections 43 12.1. GMP inspections ...... 43 12.2. GCP inspections ...... 43 12.3. Pharmacovigilance inspections ...... 43 12.4. GLP inspections ...... 43
13. Innovation Task Force 43 13.1. Minutes of Innovation Task Force ...... 43 13.2. Innovation Task Force briefing meetings ...... 43 13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 ...... 43 13.4. Nanomedicines activities ...... 44
14. Organisational, regulatory and methodological matters 44 14.1. Mandate and organisation of the CHMP ...... 44 14.2. Coordination with EMA Scientific Committees...... 44 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) ...... 44 14.2.2. Committee for Advanced Therapies (CAT) ...... 44 14.2.3. Committee for Herbal Medicinal Products (HMPC) ...... 44 14.2.4. Paediatric Committee (PDCO) ...... 44 14.2.5. Committee for Orphan Medicinal Products (COMP) ...... 45 14.2.6. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)45 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 45 14.3.1. Scientific Advice Working Party (SAWP) ...... 45 14.3.2. Name Review Group (NRG) ...... 45 14.3.3. Biologics Working Party (BWP) ...... 46 14.3.4. Safety Working Party (SWP) ...... 46
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 6/56
14.3.5. Biosimilar Medicinal Product Working Party (BMWP) ...... 46 14.3.6. Pharmacokinetics Working Party (PKWP) ...... 46 14.3.7. Oncology Working Party (ONCWP) ...... 46 14.3.8. Vaccines Working Party (VWP) ...... 46 14.4. Cooperation within the EU regulatory network ...... 47 14.5. Cooperation with International Regulators...... 47 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee ...... 47 14.7. CHMP work plan ...... 47 14.8. Planning and reporting ...... 47 14.9. Others ...... 47
15. Any other business 47 15.1. AOB topic ...... 47 15.1.1. Preparedness of the system and capacity increase ...... 47 15.1.2. Oncology Training ...... 47
16. List of participants 48 17. Explanatory notes 54
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 7/56
1. Introduction
1.1. Welcome and declarations of interest of members, alternates and experts
In accordance with the Agency’s policy on handling of declarations of interests of scientific Committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See (current) October 2019 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 14 – 17 October 2019 (to be published post November 2019 CHMP meeting).
Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.
Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.
1.2. Adoption of agenda
CHMP agenda for 14-17 October 2019
The CHMP adopted the agenda.
1.3. Adoption of the minutes
CHMP minutes for 16-19 September 2019.
The CHMP adopted the minutes via written procedure on 24 October 2019.
CHMP ORGAM minutes for 07 October 2019.
The Minutes of the October 2019 CHMP ORGAM meeting held on 07 October 2019, together with all decisions taken at that meeting, were adopted.
2. Oral Explanations
2.1. Pre-authorisation procedure oral explanations
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 8/56
2.1.1. fostamatinib - EMEA/H/C/005012
indicated for the treatment of thrombocytopenia
Scope: Oral explanation
Action: Oral explanation to be held on Thursday, 17 October 2019 at 09:00
List of Outstanding Issues adopted on 19.09.2019, 27.06.2019. List of Questions adopted on 31.01.2019.
An oral explanation was held on Thursday, 17 October 2019. The presentation by the applicant focused on the efficacy and safety data in the sought target population.
2.1.2. ciprofloxacin - EMEA/H/C/004394
treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with Pseudomonas aeruginosa (P. aeruginosa)
Scope: Oral explanation
Action: Oral explanation to be held on Tuesday, 15 October at 09:00
List of Outstanding Issues adopted on 28.03.2019. List of Questions adopted on 26.07.2018.
An oral explanation was held on Tuesday, 15 October. The presentation by the applicant focused on the efficacy and safety data in the sought indication.
2.1.3. solriamfetol - EMEA/H/C/004893
indicated to improve wakefulness in patients with narcolepsy or obstructive sleep apnoea.
Scope: Oral explanation
Action: Oral explanation to be held on 16 October 2019 at 09:00
List of Outstanding Issues adopted on 25.07.2019. List of Questions adopted on 28.03.2019.
An oral explanation was held on 16 October 2019. The presentation of the applicant concerned the clinical data in the sought indication, the posology and proposed post-authorisation measures.
2.2. Re-examination procedure oral explanations
2.2.1. Evenity - romosozumab - EMEA/H/C/004465
UCB Pharma S.A.; Treatment of osteoporosis
Scope: Oral explanation/Opinion, Report of ad-hoc expert group meeting scheduled on 3 October 2019
Letters from third parties
Action: Oral explanation to be held on Tuesday, 15 October 2019 at 14:00
Participation of patient representatives
New active substance (Article 8(3) of Directive No 2001/83/EC)
Opinion adopted on 27.06.2019, List of Outstanding Issues adopted on 29.05.2019,
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 9/56
28.02.2019, 15.11.2018, 20.09.2018. List of Questions adopted on 26.04.2018.
The CHMP noted the report from the ad-hoc expert meeting.
An oral explanation was held on Tuesday, 15 October 2019. The presentation by the applicant focused on efficacy and safety data in the proposed target population.
See 3.5
2.3. Post-authorisation procedure oral explanations
2.3.1. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0012
Pfizer Europe MA EEIG
Rapporteur: Nithyanandan Nagercoil, PRAC Rapporteur: Liana Gross-Martirosyan
Scope: “Extension application to introduce a new pharmaceutical form (prolonged-release tablet) associated with a new strength (11 mg), and presented in pack sizes of 28, 30, 90 and 91 tablets. An updated RMP (version 6.1) has been adopted.”
Possible oral explanation/Opinion
Action: Possible oral explanation to be held on Wednesday, 16 October 2019 at 15:30
List of Outstanding Issues adopted on 19.09.2019, 27.06.2019, 31.01.2019. List of Questions adopted on 26.07.2018.
The CHMP agreed that no oral explanation is needed this time.
See 4.1
2.3.2. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049
Novartis Europharm Limited
Re-examination Rapporteur: Milena Stain and re-examination Co-Rapporteur: Sinan B Sarac
Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia
Scope: “Extension of indication to include first line treatment of adult and paediatric patients aged 2 years and older with severe aplastic anaemia for Revolade in combination with IST; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 50 has also been updated.”
Oral explanation/Opinion
Report from the ad-hoc expert group meeting scheduled on 7 October 2019
Action: Oral explanation to be held on Tuesday, 15 October 2019 at 16:00
Opinion adopted on 27.06.2019. Oral explanation held on 24.06.2019. Request for Supplementary Information adopted on 28.02.2019, 15.11.2018, 26.07.2018.
The CHMP noted the report from the ad-hoc expert meeting.
An oral explanation was held on Tuesday, 15 October 2019. The presentation from the applicant mainly focused on the clinical data in support of the extension of indication as well as post authorisation measures.
See 5.3
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 10/56
2.3.3. Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0047
PTC Therapeutics International Limited
Re-examination rapporteur: Kristina Dunder, Re-examination co-rapporteur: Alexander Moreau
Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan
Scope: “Extension of indication to include non-ambulatory patients with duchenne muscular dystrophy; this variation additionally presents, as supportive data, the final results of the long term clinical study PTC-124-GD-019-DMD (an Open-Label Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy), submitted in line with the requirements of the Article 46 of the Paediatric Regulation. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 8.0 has also been submitted.”
Opinion, SAG Report
The final list of experts for the SAG Neurology was adopted via written procedure on 10 October 2019.
Action: Oral explanation to be held on Tuesday, 15 October 2019 at 11:00
Opinion adopted on 27.06.2019. Oral explanation held on 25.06.2019. Request for Supplementary Information adopted on 28.02.2019, 13.12.2018.
The CHMP noted the report from the SAG.
An oral explanation was held on Tuesday, 15 October 2019. The presentation by the applicant focused on clinical data in non-ambulatory patients and methodological clarifications on the trial conduct.
See 5.3
2.4. Referral procedure oral explanations
No items
3. Initial applications
3.1. Initial applications; Opinions
3.1.1. BAQSIMI - glucagon - EMEA/H/C/003848
Eli Lilly Nederland B.V.; treatment of severe hypoglycaemia
Scope: Opinion
Action: For adoption
Known active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.07.2019, 26.04.2019. List of Questions adopted on 13.12.2018.
The Committee confirmed that all issues previously identified in this application had been
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 11/56
addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The CHMP noted the letter of recommendation dated 11.10.2019.
The summary of opinion was circulated for information.
3.1.2. Ervebo - recombinant vesicular stomatitis virus - zaire ebolavirus vaccine (live) - EMEA/H/C/004554
Merck Sharp & Dohme B.V.; Ebola Vaccine
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 17.09.2019. List of Questions adopted on 25.06.2019.
The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live) is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendations dated 17.10.2019.
The summary of opinion was circulated for information.
3.1.3. Hopveus - sodium oxybate - EMEA/H/C/004962
D&A PHARMA; for the treatment of alcohol dependence
Scope: Opinion
Action: For adoption
Known active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 26.04.2019. List of Questions adopted on 15.11.2018.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a negative opinion by majority recommending the refusal of a marketing authorisation together with the CHMP assessment report and translation timetable.
The refusal question and answers document was circulated for information.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 12/56
3.1.4. Pegfilgrastim Mundipharma - pegfilgrastim - EMEA/H/C/005312
Mundipharma Biologics S.L.; treatment of neutropenia
Scope: Opinion
Action: For adoption
Similar biological application (Article 10(4) of Directive No 2001/83/EC)
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.
3.1.5. Quofenix - delafloxacin - EMEA/H/C/004860
A. Menarini Industrie Farmaceutiche Riunite s.r.l.; treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 19.09.2019, 29.05.2019. List of Questions adopted on 20.09.2018.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that delafloxacin is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to medical prescription.
The CHMP noted the letter of recommendation dated 17 October 2019.
The summary of opinion was circulated for information.
3.1.6. Rinvoq - upadacitinib - EMEA/H/C/004760
AbbVie Deutschland GmbH & Co. KG; treatment of moderate to severe active rheumatoid arthritis
Scope: Opinion
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 13/56
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 19.09.2019. List of Questions adopted on 29.05.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that upadacitinib is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendation dated 15 October 2019.
The summary of opinion was circulated for information.
3.1.7. Spravato - esketamine - EMEA/H/C/004535
Janssen-Cilag International N.V.; treatment-resistant depression
Scope: Opinion
Action: For adoption
Known active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 25.07.2019. List of Questions adopted on 28.02.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to special and restricted medical prescription.
The summary of opinion was circulated for information.
3.1.8. VANFLYTA - quizartinib - Orphan - EMEA/H/C/004468
Daiichi Sankyo Europe GmbH; treatment of acute myeloid leukaemia
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 27.06.2019. List of Questions adopted on 29.01.2019.
The Committee was reminded of the status of this application and its remaining outstanding
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 14/56
issues.
The Committee adopted a negative opinion by consensus recommending the refusal of a marketing authorisation together with the CHMP assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The refusal question and answers document was circulated for information.
3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)
3.2.1. adalimumab - EMEA/H/C/004879
treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis, paediatric uveitis, adolescent hidradenitis suppurativa
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 28.03.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.2. azacitidine - EMEA/H/C/005147
Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) and AML with >30% marrow blasts according to the WHO classification.
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.3. azacitidine - EMEA/H/C/005075
Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML)
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 15/56
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.4. brolucizumab - EMEA/H/C/004913
treatment of neovascular (wet) age-related macular degeneration (AMD)
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 27.06.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.5. cinacalcet - EMEA/H/C/005236
treatment of secondary hyperparathyroidism and hypercalcaemia
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.6. osilodrostat - Orphan - EMEA/H/C/004821
Novartis Europharm Limited; treatment of Cushing's syndrome
Scope: List of outstanding issues
Action: For adoption
List of Outstanding Issues adopted on 25.07.2019. List of Questions adopted on 28.03.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a 2nd list of outstanding issues with a specific timetable.
3.2.7. imipenem / cilastatin / relebactam - EMEA/H/C/004808
indicated for the treatment of bacterial infections due to gram-negative microorganisms
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 28.03.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 16/56
3.2.8. entrectinib - EMEA/H/C/004936
treatment of adult and paediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive locally advanced or metastatic solid tumours and treatment of patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC).
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.2.9. cholera vaccine, oral, live - EMEA/H/C/003876
indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 6 years and older
Scope: List of outstanding issues
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.
3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)
3.3.1. apixaban - EMEA/H/C/005358
prevention of venous thromboembolic events (VTE)
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.2. crizanlizumab - Orphan - EMEA/H/C/004874
Novartis Europharm Limited; Treatment of sickle cell disease
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 17/56
list of questions.
3.3.3. dasatinib - EMEA/H/C/005446
treatment of leukaemia
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.4. dasatinib - EMEA/H/C/005317
treatment of leukaemia
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.5. bupivacaine - EMEA/H/C/004586
Indicated for prolonged acute pain management and reduction in need for opioids in adults compared to immediate-release bupivacaine
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.6. givosiran - Orphan - EMEA/H/C/004775
Accelerated assessment
Alnylam Netherlands B.V.; Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 18/56
3.3.7. budesonide / formoterol fumarate dihydrate - EMEA/H/C/004882
treatment of asthma and COPD
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.8. insulin aspart - EMEA/H/C/005033
treatment of diabetes mellitus
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.9. obiltoxaximab - Orphan - EMEA/H/C/005169
SFL Regulatory Services GmbH; treatment of inhalational anthrax due to Bacillus anthracis
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.10. doxorubicin - EMEA/H/C/005320
treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.11. idebenone - Orphan - EMEA/H/C/005123
Santhera Pharmaceuticals (Deutschland) GmbH; treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) not using glucocorticoids
Scope: List of questions
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 19/56
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.12. lefamulin - EMEA/H/C/005048
treatment of community-acquired pneumonia (CAP)
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.13. trastuzumab - EMEA/H/C/005209
treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)
Scope: List of questions
Action: For adoption
The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.4. Update on on-going initial applications for Centralised procedure
3.4.1. pretomanid - Orphan - EMEA/H/C/005167
FGK Representative Service GmbH; treatment of tuberculosis
Scope: Request by the applicant for an extension to the clock stop to respond to the List of Questions adopted on 25.07.2019.
Action: For adoption
List of Questions adopted on 25.07.2019.
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the List of Questions adopted on 25.07.2019.
3.4.2. selinexor - Orphan - EMEA/H/C/005127
Karyopharm Europe GmbH; treatment of patients with relapsed refractory multiple myeloma (RRMM)
Scope: Request by the applicant dated 01 October 2019 for an extension to the clock stop to respond to the List of Outstanding Issues adopted on 19.09.2019
Action: For adoption
List of Outstanding Issues adopted on 19.09.2019. List of Questions adopted on 24.04.2019.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 20/56
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the List of Outstanding Issues adopted on 19.09.2019
3.4.3. bupivacaine / meloxicam - EMEA/H/C/005205
for application into the surgical site to reduce postoperative pain
Scope: Request by the applicant dated 30 September 2019 for an extension to the clock stop to respond to the List of Questions adopted on 25.07.2019
Action: For adoption
List of Questions adopted on 25.07.2019.
The CHMP agreed to the request for an extension to the clock stop to respond to the List of Questions adopted on 25.07.2019
3.4.4. viable T-cells - Orphan - ATMP - EMEA/H/C/002397
Kiadis Pharma Netherlands B.V.; adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for a malignant disease
Scope: Update on the CAT discussions at their October meeting
Action: For discussion
List of Outstanding Issues adopted on 21.06.2019, 14.09.2018, 25.05.2018. List of Questions adopted on 08.09.2017.
The CHMP was updated on discussions at the October CAT meeting.
3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004
3.5.1. Evenity - romosozumab - EMEA/H/C/004465
UCB Pharma S.A.; Treatment of osteoporosis
Scope: Oral explanation/Opinion, Report of ad-hoc expert group meeting held on 3 October 2019
Letters from third parties
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
Opinion adopted on 27.06.2019, List of Outstanding Issues adopted on 29.05.2019, 28.02.2019, 15.11.2018, 20.09.2018. List of Questions adopted on 26.04.2018.
See 2.2
The CHMP noted the report from the ad-hoc expert meeting.
An oral explanation was held on Tuesday, 15 October 2019. The presentation by the applicant focused on efficacy and safety data in the proposed target population.
The members further discussed the clinical data taking the view of the ad-hoc expert group into consideration that the efficacy has been demonstrated and the safety could be
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 21/56
manageable. The CHMP also elaborated on the possibility for a post authorisation study.
The CHMP adopted a positive opinion by majority (23 positive out of 31 votes) recommending the granting of a marketing authorisation together with the CHMP assessment report and translation timetable.
Furthermore, the CHMP considered that romosozumab is a new active substance, as claimed by the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Kristina Dunder, Christian Gaartner, Johann Lodewijk Hillege, Andrea Laslop, Konstantinos Markopoulos, Alexandre Moreau, Loizos Panayi, Concepcion Prieto Yerro) was appended to the opinion.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.
3.6. Initial applications in the decision-making phase
No items
3.7. Withdrawals of initial marketing authorisation application
3.7.1. diclofenamide - Orphan - EMEA/H/C/005141
Sun Pharmaceutical Industries Europe B.V.; treatment of periodic paralysis
Scope: Letter from the applicant dated 02 October 2019 informing about the withdrawal of marketing authorisation application
Action: For information
List of Questions adopted on 29.05.2019.
The CHMP noted the withdrawal of marketing authorisation application.
3.7.2. omadacycline - EMEA/H/C/004715
treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults
Scope: Letter from the applicant dated 09 October 2019 informing about the withdrawal of marketing authorisation application
Action: For information
List of Outstanding Issues adopted on 19.09.2019, 27.06.2019. List of Questions adopted on 31.01.2019.
The CHMP noted the withdrawal of marketing authorisation application.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 22/56
4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008
4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion
4.1.1. Kalydeco - ivacaftor - Orphan - EMEA/H/C/002494/X/0075/G
Vertex Pharmaceuticals (Ireland) Limited
Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon
Scope: “Extension application to add a new strength of 25 mg granules in sachet in the treatment of cystic fibrosis in children aged 6 to less than 12 months old. C.I.4 - Updates to sections 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC, and the PL for the 150 mg film-coated tablet presentations to bring it in line with the new dosage form (25 mg granules), which supports the extension of indication for children aged 6 to 12 months old. The RMP (version 8.3) is updated in accordance. In addition, the MAH took the opportunity to implement minor updates in the Product Information.”
Action: For adoption
List of Outstanding Issues adopted on 25.07.2019. List of Questions adopted on 26.04.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
4.1.2. Xeljanz - tofacitinib - EMEA/H/C/004214/X/0012
Pfizer Europe MA EEIG
Rapporteur: Nithyanandan Nagercoil, PRAC Rapporteur: Liana Gross-Martirosyan
Scope: “Extension application to introduce a new pharmaceutical form (prolonged-release tablet) associated with a new strength (11 mg), and presented in pack sizes of 28, 30, 90 and 91 tablets. An updated RMP (version 6.1) has been adopted.”
Action: For adoption
List of Outstanding Issues adopted on 19.09.2019, 27.06.2019, 31.01.2019. List of Questions adopted on 26.07.2018.
See 2.3
The CHMP agreed that no oral explanation is needed this time.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 23/56
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues
4.2.1. Dificlir - fidaxomicin - EMEA/H/C/002087/X/0034/G
Astellas Pharma Europe B.V.
Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga
Scope: “Extension application to introduce a new pharmaceutical form associated with new strength (40 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use of Dificlir in children from birth to less than 18 years of age. The RMP (version 11.0) is updated in accordance. Consequential updates have been made to the SmPC of Dificlir 200 mg Film-coated tablet. The labelling and package leaflet (PL) are updated accordingly. The PL is also being amended to include a statement that Dificlir is essentially ‘sodium-free' (in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'). The details of the local representative of the MAH in the Czech Republic are also updated.”
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee discussed the issues identified in this application, mainly relating to some SmPC updates.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.
4.2.2. Emgality - galcanezumab - EMEA/H/C/004648/X/0004
Eli Lilly Nederland B.V.
Rapporteur: Daniela Melchiorri (IT) (MNAT with ES for Quality), Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Kirsti Villikka
Scope: “Extension application to add a new strength of 100 mg/ml solution for injection in pre-filled syringe for Emgality, associated with a new indication (episodic cluster headache).”
Action: For adoption
List of Questions adopted on 27.06.2019.
The Committee discussed the issues identified in this application, mainly relating to efficacy in episodic cluster headaches.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.
The CHMP agreed to consult a SAG. The list of questions will be adopted by written procedure after the Plenary.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 24/56
4.2.3. Vyndaqel - tafamidis - Orphan - EMEA/H/C/002294/X/0049/G
Pfizer Europe MA EEIG
Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ghania Chamouni
Scope: “Extension application to: - introduce a new strength (tafamidis 61 mg soft capsules, pack-size of 30 and 90 capsules) including a new indication "treatment of transthyretin amyloidosis in adult patients with wild-type or hereditary cardiomyopathy to reduce all-cause mortality and cardiovascular-related hospitalisation (ATTR-CM)" - introduce qualitative change in declared active substance (tafamidis) not defined as a new active substance; grouped with a type II variation (C.I.4) to update section 4.6 of the Vyndaqel (tafamidis meglumine) 20 mg soft capsules SmPC to add wording pertaining to the Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) programme. Submission of an updated RMP version 9.0 in order to include the proposed new dosage/indication, review of the additional data collected from the ATTR-CM clinical program and post marketing reporting, reclassification of the safety concerns, remove of HCP educational leaflet. Relevant changes are proposed for Annex II. In addition, the MAH is proposing an update to Section 16 Information in Braille of Annex IIIa - Labelling (carton) to differentiate between the dosage forms.”
Action: For adoption
List of Questions adopted on 29.05.2019.
The Committee discussed the issues identified in this application, concerning the appropriate indication wording.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of questions
4.3.1. Harvoni - ledipasvir / sofosbuvir - EMEA/H/C/003850/X/0081/G
Gilead Sciences Ireland UC
Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: “Extension application to introduce a new strength (45/200 mg film-coated tablets) and a new pharmaceutical form (oral granules) associated with new strengths (33.75/150 and 45/200 mg). The new presentations are indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in patients aged 3 to <12 years. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 3 to < 12 years who weigh greater than or equal to 35 kg to the existing presentations of 90/400 mg film-coated tablets. The RMP (version 8.3) is updated in accordance. In addition, the MAH took the opportunity to implement minor linguistic corrections throughout the Product Information.”
Action: For adoption
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 25/56
The Committee discussed the issues identified in this application, mainly concerning some quality aspects and an updated environmental risk assessment.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
4.3.2. Sovaldi - sofosbuvir - EMEA/H/C/002798/X/0059/G
Gilead Sciences Ireland UC
Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: “Extension application to introduce a new strength (200 mg film-coated tablets) and a new pharmaceutical form (oral granules) associated with new strengths (150 and 200 mg). The new presentations are indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in patients aged 3 to <12 years. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 3 to < 12 years who weigh greater than or equal to 35 kg to the existing presentations of 400 mg film-coated tablets. The RMP (version 8.3) is updated in accordance. In addition, the MAH took the opportunity to implement minor linguistic corrections throughout the Product Information.”
Action: For adoption
The Committee discussed the issues identified in this application, mainly concerning some quality aspects and an updated environmental risk assessment.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008
No items
4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008
No items
5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008
5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information
5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0070
Takeda Pharma A/S
Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 26/56
Rapporteur: Menno van der Elst
Scope: “treatment of adults with previously untreated CD30+ PTCL”
Action: For adoption
The Committee discussed the issues identified in this application, mainly concerning efficacy data in different subgroups.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.2. Carmustine Obvius - carmustine - EMEA/H/C/004326/II/0002
Obvius Investment B.V
Rapporteur: Natalja Karpova, PRAC Rapporteur: Jan Neuhauser
Scope: “carmustine with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases”
Action: For adoption
The Committee discussed the issues identified in this application, mainly regarding the wording of the indication.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.3. Cyramza - ramucirumab - EMEA/H/C/002829/II/0033
Eli Lilly Nederland B.V.
Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Kolbeinn Gudmundsson (IS) (MNAT with FI for Quality, FI for Non-Clinical, LT for Clinical Pharmacology), PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: “Extension of indication for Cyramza, to include in combination with erlotinib, the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated accordingly. The RMP version 9 has also been submitted.”
Action: For adoption
The Committee discussed the issues identified in this application, relating to some aspect regarding clinical efficacy and safety as well as the RMP.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.4. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0029
Janssen-Cilag International NV
Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva
Scope: “Extension of indication to extend the existing therapeutic indication for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 27/56
stem cell transplant (ASCT); as a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (Version 6, Succession 1) has also been submitted.”
Action: For adoption
Request for Supplementary Information adopted on 25.07.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
5.1.5. Darzalex - daratumumab - Orphan - EMEA/H/C/004077/II/0030
Janssen-Cilag International NV
Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva
Scope: “Extension of indication to extend the existing therapeutic indication for Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (Version 6, Succession 1) has also been submitted.”
Action: For adoption
Request for Supplementary Information adopted on 25.07.2019.
The Committee discussed the issues identified in this application, mainly relating to the clinical efficacy of the new regimen.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0065
Merck Sharp & Dohme B.V.
Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst
Scope: “Extension of indication to include, as monotherapy or in combination with platinum and 5-fluorouracil (5-FU) Chemotherapy, first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in adults for Keytruda; based on the results from KEYNOTE-048, a randomized, multi-center, open-label phase 3 study investigating pembrolizumab, or pembrolizumab plus platinum plus 5-FU chemotherapy versus platinum plus 5-FU plus cetuximab in subjects with first-line recurrent or metastatic HNSCC. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (Version 22.1) is also being submitted.”
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 28/56
Action: For adoption
Request for Supplementary Information adopted on 19.09.2019, 27.06.2019, 28.03.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
5.1.7. Lynparza - olaparib - EMEA/H/C/003726/II/0033
AstraZeneca AB
Rapporteur: Alexandre Moreau, Co-Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Amelia Cupelli
Scope: “Extension of indication to support the use of Lynparza tablets (100 mg and 150 mg) for the maintenance treatment of gBRCAm metastatic pancreatic cancer based on the results from the pivotal Phase 3 study, POLO; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.8 for Lynparza hard capsules (50 mg) to revise list of ADR based on the pooled safety data analysis. The RMP version 18 has also been submitted. Furthermore, the PI is brought in line with the latest guideline regarding the sodium content. The MAH also took the occasion to include some minor editorial changes in the PI.”
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to the efficacy and the external validity of the results.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.8. MabThera - rituximab - EMEA/H/C/000165/II/0162
Roche Registration GmbH
Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Hans Christian Siersted
Scope: “Extension of indication to include the treatment of paediatric patients (aged ≥ 2 to <18 years old) with active polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA), for MA numbers EU/1/98/067/001-002 for MabThera; following efficacy and safety data from Clinical study report (CSR) WA25615 (also known as Paediatric Polyangiitis and Rituximab Study [PePRS]) which was conducted to fulfil the measure of the Paediatric Investigational Plan (PIP: EMEA-000308-PIP02-11-M01) agreed upon in the context of rituximab development for treatment of adult patients with GPA and MPA (RAVE study). The CSR for Study 1: WA 25615 was submitted on 30th Oct 2018 as the Post Approval Measure submission according to Article 46 requirement. Linked to this variation the final compliance check procedure to close the PIP has started 3rd January 2019. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and sections 2, 3 and
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 29/56
4 of the Package Leaflet are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template (version 10) and the opportunity is taken to combine the SmPC and PIL for 100 mg and 500 mg IV as they are identical except for strength specifications. In addition, the applicant took the opportunity to implement minor editorial changes in the SmPC. The RMP version 20.0 has also been submitted.”
Action: For adoption
Request for Supplementary Information adopted on 29.05.2019.
The Committee discussed the issues identified in this application, mainly concerning the wording of the indication with regard to the paediatric population and post authorisation measures.
The Committee adopted a 2nd request for supplementary information with a specific timetable.
5.1.9. Otezla - apremilast - EMEA/H/C/003746/II/0029
Celgene Europe BV
Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Eva A. Segovia
Scope: “Extension of indication to include treatment of adult patients with oral ulcers associated with Behçet’s disease (BD) who are candidates for systemic therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC and sections 1, 2 and 4 of the PL are updated accordingly. The updated RMP version 12.0 has also been submitted.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to the request for 1 year of market protection.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.10. Rezolsta - darunavir / cobicistat - EMEA/H/C/002819/II/0033
Janssen-Cilag International NV
Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ilaria Baldelli
Scope: “To extend the approved therapeutic indication of Rezolsta to include the adolescent population (aged 12 years old and older with body weight at least 40 kg). As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and sections 1, 2 and 3 of the PL are updated accordingly. The updated RMP version 6.0 has also been submitted. The RMP of the product has been updated to meet the requirements and updated definitions in the European Medicines Agency (EMA) Guideline on good pharmacovigilance practices (GVP) Module V Revision 2 (EMA/838713/2011; Rev 2) and Guidance on the format of the RMP in the European Union (EMA/164014/2018 Rev 2.0.1) including proposed removal of safety concerns. In addition, in order to align the PI with recommendations for other HIV products, the MAH has also taken the opportunity to update section 4.2 of the SmPC with regards to administration of Rezolsta in case of vomiting.”
Action: For adoption
The Committee discussed the issues identified in this application, relating to some clinical aspects and the RMP.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 30/56
The Committee adopted a request for supplementary information with a specific timetable.
5.1.11. SIRTURO - bedaquiline - Orphan - EMEA/H/C/002614/II/0033/G
Janssen-Cilag International NV
Rapporteur: Filip Josephson, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga
Scope: “Grouping of an extension of indication to include patients 12 years of age and older for Sirturo and a Type II variation to change the safety information in Section 4.9 of the SmPC. The extension of indication is supported by the Week 24 analysis of Cohort 1 (adolescent subjects aged ≥12 to <18 years) of Study TMC207-C211. Based on these data, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (version 3.2) was included in the submission.”
Action: For adoption
Request for Supplementary Information adopted on 19.09.2019, 29.05.2019, 31.01.2019.
The Committee discussed the issues identified in this application concerning updates of the SmPC.
The Committee adopted a 4th request for supplementary information with a specific timetable.
5.1.12. Stelara - ustekinumab - EMEA/H/C/000958/II/0073
Janssen-Cilag International NV
Rapporteur: Jayne Crowe, Co-Rapporteur: Mark Ainsworth, PRAC Rapporteur: Rhea Fitzgerald
Scope: “Extension of indication to include a new population for Stelara solution for injection in children aged 6 to 12 years with moderate to severe psoriasis based on the results of study CNTO1275PSO3013; as a consequence sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated accordingly. The Package Leaflet is updated in accordance. Section 4.8 for Stelara concentrate for solution for infusion is updated accordingly. Minor editorial changes are made to section 4.5 for both formulations. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 15.0 has also been submitted. The MAH took the opportunity to add “follow-up of pregnancy registry” in Part III.1 of the RMP in line with the existing information in Part V.3 of the RMP.”
Action: For adoption
The Committee discussed the issues identified in this application relating to some quality and clinical aspects as well as the RMP.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.13. Suliqua - insulin glargine / lixisenatide - EMEA/H/C/004243/II/0011
sanofi-aventis groupe
Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst
Scope: “Extension of indication to include “treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 31/56
addition to other oral medicinal products for the treatment of diabetes” based on the phase 3 Study EFC13794; a 26-week randomized, open-label, active controlled, parallel-group, study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin (alone or with pioglitazone and/or SGLT2 inhibitors), followed by a fixed ratio combination single-arm 26-week extension period. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the contact details of the local representatives in Denmark, the Netherlands and the UK in the Package Leaflet and to implement minor editorial changes in the annexes. An updated RMP version 4.0 was provided as part of the application.”
Action: For adoption
Request for Supplementary Information adopted on 27.06.2019.
The Committee discussed the issues identified in this application, mainly relating to the indication wording.
The Committee adopted a 2nd request for supplementary information with a specific timetable.
5.1.14. Toujeo - insulin glargine - EMEA/H/C/000309/II/0108
Sanofi-Aventis Deutschland GmbH
Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst
Scope: “Extension of indication to include new population for Toujeo (i.e. adolescents and children from the age of 6 years). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.”
Action: For adoption
Request for Supplementary Information adopted on 27.06.2019.
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
The CHMP adopted the similarity assessment report.
5.1.15. Tybost - cobicistat - EMEA/H/C/002572/II/0051
Gilead Sciences Ireland UC
Rapporteur: Bruno Sepodes, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: “To modify the approved therapeutic indication to include new population (adolescents aged 12 years and older weighing at least 35 kg) for the treatment of HIV-1. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 of the SmPC and sections 1, 2, 3 of the PL are updated
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 32/56
accordingly. The updated RMP version 4.1 is also been submitted”
Action: For adoption
The Committee discussed the issues identified in this application, relating to some non-clinical and clinical aspects as well as the RMP.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.16. Venclyxto - venetoclax - EMEA/H/C/004106/II/0023/G
AbbVie Deutschland GmbH & Co. KG
Rapporteur: Filip Josephson, PRAC Rapporteur: Eva Jirsová
Scope: “Extension of the indication to include treatment with Venclyxto in combination with an anti‐CD20 antibody (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) based on the results of the pivotal CLL14/BO25323 phase 3 study. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1 of the SmPC and corresponding sections of the PL have been revised. The updated RMP version 5.1 has been submitted. Additionally, the SmPC section 5.3 has been updated based on the 6 month carcinogenicity mouse study report, supported by the 4 week dose ranging study in mice and the embryo-foetal development (EFD) data. Minor editorial changes have been introduced throughout the PI.”
Action: For adoption
The Committee discussed the issues identified in this application, mainly concerning the wording of the indication.
The Committee adopted a request for supplementary information with a specific timetable.
5.1.17. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G
Astellas Pharma Europe B.V.
Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia
Scope: “C.1.6: Extension of indication to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for Xtandi in combination with androgen deprivation therapy; As a consequence, sections 4.1, 4.7, 4.8, 5.1, 5.3 and 6.6 of the SmPC are updated. Furthermore the MAH took the opportunity to make corrections to section 4.7. The Package Leaflet is updated in accordance. The RMP version 13.0 has also been submitted. C.1.4: Update of section 5.1 of the SmPC based on the 5-year Overall Survival (OS) results obtained from the PREVAIL study (MDV310003), a phase 3 study of enzalutamide in chemotherapy naïve patients with metastatic prostate cancer that progressed on ADT.”
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to the clinical trial.
The Committee adopted a request for supplementary information with a specific timetable.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 33/56
5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008
5.2.1. Axumin - fluciclovine (18F) - EMEA/H/C/004197/II/0011
Blue Earth Diagnostics Ireland Limited
Rapporteur: Janet Koenig, PRAC Rapporteur: Rugile Pilviniene
Scope: “Extension of indication to include diagnosis and continuing assessment of Glioma in adult patients as a new indication for Axumin; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 5.1, 5.2 and 11 of the SmPC and the Annex II are updated. The Package Leaflet is updated in accordance. Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
Request by the applicant for an extension to the clock stop to respond to the Request for Supplementary Information adopted on 25.07.2019
Action: For adoption
Request for Supplementary Information adopted on 25.07.2019, 28.03.2019.
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the Request for Supplementary Information adopted on 25.07.2019.
5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008
5.3.1. Revolade - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/II/0049
Novartis Europharm Limited
Re-examination Rapporteur: Milena Stain and re-examination Co-Rapporteur: Sinan B Sarac
Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia
Scope: “Extension of indication to include first line treatment of adult and paediatric patients aged 2 years and older with severe aplastic anaemia for Revolade in combination with IST; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 50 has also been updated.”
Oral explanation/opinion
Report from the ad hoc expert group meeting held on 7 October 2019
Action: For adoption
Opinion adopted on 27.06.2019. Oral explanation held on 24.06.2019. Request for Supplementary Information adopted on 28.02.2019, 15.11.2018, 26.07.2018.
An oral explanation was held on Tuesday, 15 October 2019. The presentation from the applicant mainly focused on the clinical data in support of the extension of indication as well as proposed post-authorisation measures.
See 2.3
The CHMP adopted a final negative opinion by majority (27 negative out of 29 votes)
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 34/56
recommending the refusal of the extension of indication together with the CHMP assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Sinan B Sarac, Bruno Sepodes) was appended to the opinion.
The refusal question and answers document was circulated for information.
5.3.2. Translarna - ataluren - Orphan - EMEA/H/C/002720/II/0047
PTC Therapeutics International Limited
Re-examination rapporteur: Kristina Dunder, Re-examination co-rapporteur: Alexander Moreau
Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan
Scope: “Extension of indication to include non-ambulatory patients with Duchenne muscular dystrophy; this variation additionally presents, as supportive data, the final results of the long term clinical study PTC-124-GD-019-DMD (an Open-Label Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy), submitted in line with the requirements of the Article 46 of the Paediatric Regulation. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 8.0 has also been submitted.”
Opinion, SAG Report
Action: For adoption
Opinion adopted on 27.06.2019. Oral explanation held on 25.06.2019. Request for Supplementary Information adopted on 28.02.2019, 13.12.2018.
See 2.3
The CHMP noted the report from the SAG.
An oral explanation was held on Tuesday, 15 October 2019. The presentation by the applicant focused on clinical data in non-ambulatory patients and methodological clarifications on the trial conduct.
The Committee adopted a final negative opinion by consensus recommending the refusal of the extension of indication together with the CHMP assessment report.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The refusal question and answers document was circulated for information.
6. Ancillary medicinal substances in medical devices
6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions
No items
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 35/56
6.2. Update of Ancillary medicinal substances in medical devices
No items
7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)
7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)
No items
8. Pre-submission issues
8.1. Pre-submission issue
8.1.1. autologous CD34+ enriched cell fraction that contains CD34+ cells genetically modified ex vivo using a lentiviral vector encoding for the human arylsulfatase A(ARSA) cDNA sequence - Orphan - ATMP - H0005321
Orchard Therapeutics (Netherlands) BV; Treatment of patients with Metachromatic Leukodystrophy (MLD)
Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.
Action: For adoption
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.
8.1.2. valoctocogene roxaparvovec - ATMP - H0004749
Treatment of Haemophilia A
Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.
Action: For adoption
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.
8.1.3. ICOSAPENT ETHYL - H0005398
intended to reduce cardiovascular risk as an adjunct to statin therapy in adult patients with elevated triglyceride levels and other risk factors for cardiovascular disease.
Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.
Action: For adoption
The CHMP did not agree to the request for accelerated assessment and adopted the briefing
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 36/56
note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.
8.1.4. Baloxavir marboxil - H0004974
indicated for the treatment of influenza in patients aged 12 and above who have been symptomatic for no more than 48 hours. indicated for treatment of influenza in patients aged 12 and above who have been symptomatic for no more than 48 hours, and are at high risk of developing influenza complications. indicated for the post-exposure prophylaxis of influenza in patients aged 12 and above.
Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.
Action: For adoption
The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.
8.2. Priority Medicines (PRIME)
Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information
8.2.1. List of applications received
Action: For information
The CHMP noted the list.
8.2.2. Recommendation for PRIME eligibility
Action: For adoption
The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 6 recommendations for eligibility to PRIME: 3 were granted and 3 were denied. In addition 1 request was withdrawn after the start of procedure.
The individual outcomes are listed in PRIME Monthly Report on EMA website.
9. Post-authorisation issues
9.1. Post-authorisation issues
9.1.1. OCALIVA - obeticholic acid – Orphan - EMEA/H/C/004093/R/0018
Intercept Pharma International Limited
Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Menno van der Elst
Scope: Renewal
Request for Supplementary Information adopted on 19.09.2019.
The Committee discussed the issues identified in this application. The members were informed
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 37/56
about the outcome of the consultation of the Gastroenterology Drafting Group.
The Committee adopted a 2nd request for supplementary information with a specific timetable.
9.1.2. Zalmoxis - nalotimagene carmaleucel – Orphan, ATMP - EMEA/H/C/002801
MolMed S.p.A
Rapporteur: Carla Herberts, Co-Rapporteur: Sol Ruiz, CHMP Coordinators: Paula Boudewina van Hennik and Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Withdrawal of marketing authorisation
Action: For information
The CHMP noted the withdrawal of marketing authorisation.
9.1.3. WS1636/G Mekinist-EMEA/H/C/002643/WS1636/0035/G Tafinlar-EMEA/H/C/002604/WS1636/0040/G
Novartis Europharm Limited
Lead Rapporteur: Filip Josephson
Scope: “Update of section 5.1 of the Mekinist (trametinib) and Tafinlar (dabrafenib) SmPC to include the 5-years overall survival (OS) results from study MEK115306 (COMBI-d), a phase III, randomised, double-blinded study comparing the combination of dabrafenib and trametinib to dabrafenib and placebo in first-line therapy for subjects with unresectable or metastatic BRAF V600/K mutation-positive cutaneous melanoma and the 5-years overall survival (OS) results from study MEK116513 (COMBI-v), a phase III, open-label, 2 arm, randomised study comparing dabrafenib and trametinib combination therapy with vemurafenib monotherapy in BRAF V600 mutation-positive metastatic melanoma.”
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to some SmPC updates.
The Committee adopted a request for supplementary information with a specific timetable.
9.1.4. WS1683 Elebrato Ellipta-EMEA/H/C/004781/ WS1683/0012 Temybric Ellipta-EMEA/H/C/005254/ WS1683/0001 Trelegy Ellipta-EMEA/H/C/004363/ WS1683/0010
GlaxoSmithKline Trading Services Limited
Lead Rapporteur: Peter Kiely
Scope: “Update of SmPC in order to add information in section 5.1 on survival data from the IMPACT study”
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to some clinical efficacy aspects.
The Committee adopted a request for supplementary information with a specific timetable.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 38/56
9.1.5. Zynteglo - autologous cd34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene - EMEA/H/C/003691/II/0001/G, Orphan, ATMP
bluebird bio (Netherlands) B.V
Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik
Scope: quality variation
Request for Supplementary Information adopted on 13.09.2019.
The Committee was updated on discussions at the October CAT meeting.
The Committee adopted a positive opinion by consensus based on the CAT opinion together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.
9.1.6. Infanrix hexa – PAM – EMEA/H/C/000296
GlaxoSmithkline Biologicals SA
Rapporteur: Bart van der Schueren, Co-Rapporteur: Jan Mueller-Berghaus
Scope: VWP consultation
Action: For adoption
The Committee discussed the issues identified in this application, mainly relating to maternal vaccination.
The Committee adopted a request for supplementary information with a specific timetable.
The CHMP agreed to consult the VWP.
10. Referral procedures
10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004
No items
10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004
10.2.1. Presence of nitrosamine impurities in human medicinal products containing chemically synthesised active pharmaceutical ingredients EMEA/H/A-5(3)/1490
MAHs: various
Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder
Scope: Building on the Article 31 referral on sartans with a tetrazole ring and the knowledge acquired on nitrosamines in medicinal products, EMA together with the EU Network has
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 39/56
continued the review to identify if there are any consequences for medicinal products outside the class of sartans. EMA has been liaising with international partners to ensure concerted actions if relevant.
The evaluation that has been conducted so far has resulted in a common understanding that it would be appropriate as a means of precaution to ask all MAHs and manufacturers to review the potential risk for N-nitrosamines as part of their medicinal products containing chemically synthesised active pharmaceutical ingredients authorised in the EU and to ensure that their medicinal products are in line with the latest knowledge on the risk of formation of or contamination with nitrosamines.
Taking into account that nitrosamines have been found in sartans with a tetrazole ring and also in some batches of pioglitazone, it is foreseen that the CHMP’s opinion is sought in accordance with Article 5(3) of Regulation (EC) No 726/2004 on the following to further investigate the issues at stake.
Updated question and answer document
Action: For discussion
The CHMP agreed to the updated question and answer document.
10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004
No items
10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC
10.4.1. Flurbiprofen Geiser – oromucosal spray – EMEA/H/A-29(4)/1487
Geiser Pharma S.L.
Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Johann Lodewijk Hillege
Scope: Opinion
Action: For adoption
The applicant has submitted a hybrid application under Article 10(3) of Directive 2001/83/EC for Flurbiprofen Geiser 8.75mg oromucosal spray. NL is of the opinion that the therapeutic equivalence between the reference and test product has not been adequately demonstrated since no clinical trials have been submitted and the justification for the absence of clinical trials is not considered acceptable.
The CHMP adopted an opinion by majority (24 out of 31 votes), recommending that the marketing authorisation(s) should be granted. The assessment report and translation timetable were adopted.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The divergent position (Jayne Crowe, Johann Lodewijk Hillege, Konstantinos Markopoulos, Alexandre Moreau, Jan Mueller-Berghaus, Nithyanandan Nagercoil, Martina Weise) was appended to the opinion.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 40/56
10.4.2. Budesonide SUN – budesonide – EMEA/H/A-29(4)/1492
Sun Pharmaceutical Industries Europe B.V.
Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Giuseppa Pistritto
Scope: Start of procedure, appointment of Rapporteurs, list of questions, timetable
Action: For adoption
The applicant has submitted an Art. 10(3) application for Budesonide SUN nebuliser suspension and associated names. Concerns regarding the demonstration of bioequivalence have been raised by IT and UK who were of the view that the data presented (comparative in vitro data of the product before nebulisation, including Particle Size Distribution (PSD) of the active substance) are not sufficient to demonstrate bioequivalence. The procedure was initiated because of disagreements regarding which in-vitro data are considered pivotal.
The CHMP appointed Johann Lodewijk Hillege as Rapporteur and Giuseppa Pistritto as Co-Rapporteur.
The CHMP adopted a list of questions with a specific timetable.
Submission of responses: 12.12.2019
Re-start of the procedure: 02.01.2020
Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 10.01.2020
Comments: 17.01.2020
Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 23.01.2020
CHMP list of outstanding issues/CHMP opinion: January 2020 CHMP
10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC
No items
10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC
10.6.1. Gadolinium-containing contrast agents (GdCA): Gadobutrol (NAP); gadodiamide (NAP); gadopentetic acid (NAP); gadoteric acid (NAP); gadoteridol (NAP); gadoxetic acid (NAP) - EMEA/H/A-31/1097
Applicant: various
Lead Rapporteur: Johann Lodewijk Hillege
Scope: Annual cumulative reviews on NSF cases submission as a post-authorisation measure resulting from the 2010 Article 20 and Article 31 referral procedures for gadolinium-containing contrast agents
Opinion
Action: For adoption
The CHMP adopted the annual cumulative reviews.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 41/56
10.6.2. Methocarbamol/Paracetamol– EMEA/H/A-31/1484
FAES FARMA, S.A., DiaMed Beratungsgesellschaft fuer pharmazeutische Unternehmen mbH
Rapporteur: Romaldas Maciulaitis, Co-Rapporteur: Jorge Camarero Jimenez
Scope: List of Outstanding Issues
Action: For adoption
Review of the benefit-risk balance following notification by BfArM in Germany on 27 May 2019 of a referral under Article 31 of Directive 2001/83/EC.
The CHMP adopted a list of outstanding issues with a specific timetable.
Submission of responses: 08.11.2019
Re-start of the procedure: 14.11.2019
Rapporteurs’ joint assessment report circulated to CHMP: 29.11.2019
Comments: 04.12.2019
Updated Rapporteurs’ joint assessment report circulated to CHMP: 06.12.2019
CHMP list of outstanding issues/CHMP opinion: December 2019 CHMP
10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC
No items
10.8. Procedure under Article 107(2) of Directive 2001/83/EC
No items
10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003
No items
10.10. Procedure under Article 29 of Regulation (EC) 1901/2006
No items
10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008
No items
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 42/56
11. Pharmacovigilance issue
11.1. Early Notification System
October 2019 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.
Action: For information
12. Inspections
12.1. GMP inspections
Information related to GMP inspections will not be published as it undermines the purpose of such inspections
12.2. GCP inspections
Information related to GCP inspections will not be published as it undermines the purpose of such inspections
12.3. Pharmacovigilance inspections
Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections
12.4. GLP inspections
Information related to GLP inspections will not be published as it undermines the purpose of such inspections
13. Innovation Task Force
13.1. Minutes of Innovation Task Force
Action: For information
13.2. Innovation Task Force briefing meetings
Information related to briefing meetings taking place with applicants cannot be released at the present time as it is deemed to contain commercially confidential information
No items
13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004
No items
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 43/56
13.4. Nanomedicines activities
No items
14. Organisational, regulatory and methodological matters
14.1. Mandate and organisation of the CHMP
CHMP-PRAC Strategic Review and Learning Meeting (SRLM) under the Finnish presidency of the European Union (EU) Council – Helsinki, Finland, 21-23 October 2019
Final agenda
Action: For information
The CHMP noted the final agenda for the CHMP-PRAC SRLM.
14.2. Coordination with EMA Scientific Committees
14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)
Summary of recommendations and advice of PRAC meeting held on 30 September - 03 October 2019
Action: For information
The CHMP noted the Summary of recommendations and advice.
List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for October 2019
Action: For adoption
The CHMP adopted the EURD list.
14.2.2. Committee for Advanced Therapies (CAT)
CAT draft minutes of meeting held on 09-11 October 2019
Action: For information
The CHMP noted the draft minutes.
14.2.3. Committee for Herbal Medicinal Products (HMPC)
Report from the HMPC meeting held on 23-24 September 2019
Action: For information
The CHMP noted the report.
14.2.4. Paediatric Committee (PDCO)
PIPs reaching D30 at October 2019 PDCO
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 44/56
Action: For information
The CHMP noted the information.
Report from the PDCO meeting held on 15-18 October 2019
Action: For information
The CHMP noted the report.
14.2.5. Committee for Orphan Medicinal Products (COMP)
Report from the COMP meeting held on 08-10 October 2019
Action: For information
The CHMP noted the report.
14.2.6. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)
Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 15-17 October 2019
Action: For information
The CHMP noted the report.
14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups
14.3.1. Scientific Advice Working Party (SAWP)
Chair: Anja Schiel
Report from the SAWP meeting held on 30 September - 03 October 2019. Table of conclusions
Action: For information
The CHMP noted the report.
Scientific advice letters:
Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.
14.3.2. Name Review Group (NRG)
Table of Decisions of the NRG meeting held on 17-18 September 2019
Action: For adoption
The CHMP adopted the Table of Decisions.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 45/56
14.3.3. Biologics Working Party (BWP)
Chair: Sol Ruiz/Nanna Aaby Kruse
Reports from BWP October 2019 meeting to CHMP for adoption:
- 14 reports on products in scientific advice and protocol assistance
- 8 reports on products in pre-authorisation procedures
- 2 reports on products in plasma master file
Action: For adoption
The CHMP adopted the BWP reports.
14.3.4. Safety Working Party (SWP)
Chair: Jan Willem Van der Laan
Election of SWP vice-chair
Mikael Andersson’s first 3-year term expired in October 2019.
The CHMP elected Susanne Brendler-Schwaab (DE) as new SWP Vice-chair.
14.3.5. Biosimilar Medicinal Product Working Party (BMWP)
Chair(s): Elena Wolff-Holz/Niklas Ekman
Election of BMWP chair
Elena Wolff-Holz’s first 3-year term expired in October 2019.
The CHMP re-elected Elena Wolff-Holz (DE) as BMWP chair.
14.3.6. Pharmacokinetics Working Party (PKWP)
Chair(s): Jan Welink/Henrike Potthast
Election of PKWP chair
Jan Welink’s second 3-year term expired in September 2019.
Nominations should to be sent.
14.3.7. Oncology Working Party (ONCWP)
Chair(s): Sinan B. Sarac /Paolo Foggi
Election of ONCWP vice-chair
Paolo Foggi’s first 3-year term expired in October 2019.
The CHMP re-elected Paolo Foggi (IT) as OncWP vice-chair.
14.3.8. Vaccines Working Party (VWP)
Chair(s): Mair Powell
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 46/56
Election of VWP chair
Mair Powell’s first 3-year term expired in October 2019.
The CHMP re-elected Mair Powell (IE) as VWP chair.
14.4. Cooperation within the EU regulatory network
No items
14.5. Cooperation with International Regulators
No items
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee
No items
14.7. CHMP work plan
No items
14.8. Planning and reporting
No items
14.9. Others
No items
15. Any other business
15.1. AOB topic
15.1.1. Preparedness of the system and capacity increase
Action: For information
15.1.2. Oncology Training
Action: For information
The Oncology training took place at the end of the Plenary meeting.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 47/56
16. List of participants
List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the October 2019 CHMP meeting.
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI Harald Enzmann Chair Germany No interests declared Andrea Laslop Member Austria No interests declared Milena Stain Alternate Austria No interests declared Bart Van der Member Belgium No interests Schueren declared Mila Vlaskovska Member Bulgaria No interests declared Margareta Bego Member Croatia No interests declared Loizos Panayi Member Cyprus No interests declared Ondřej Slanař Member Czech No interests Republic declared Sinan B. Sarac Member Denmark No interests declared Mark Ainsworth Alternate Denmark No interests declared Alar Irs Member Estonia No restrictions applicable to this meeting Outi Mäki-Ikola Member Finland No restrictions applicable to this meeting Tuomo Alternate Finland No interests Lapveteläinen declared Alexandre Moreau Member France No interests declared Jean-Michel Race Alternate France No interests declared Martina Weise Member Germany No restrictions applicable to this meeting Janet Koenig Alternate Germany No interests declared Konstantinos Member Greece No interests Markopoulos declared Melinda Sobor Member Hungary No restrictions applicable to this meeting Agnes Gyurasics Alternate Hungary No interests declared Hrefna Alternate Iceland No interests Gudmundsdottir declared Jayne Crowe Member Ireland No interests
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 48/56
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI declared Peter Kiely Alternate Ireland No interests declared Giuseppa Pistritto Alternate Italy No interests declared Natalja Karpova Member Latvia No interests declared Romaldas Member Lithuania No interests Mačiulaitis declared Martine Trauffler Member Luxembourg No interests declared John Joseph Borg Member Malta No interests declared Johann Lodewijk Member Netherlands No interests Hillege declared Paula Boudewina Alternate Netherlands No interests van Hennik declared Bjorg Bolstad Member Norway No restrictions applicable to this meeting Ingrid Wang Alternate Norway No interests declared Ewa Balkowiec Member Poland No interests Iskra declared Bruno Sepodes Member Portugal No interests (Vice-Chair) declared Fatima Ventura Alternate Portugal No restrictions applicable to this meeting Simona Badoi Member Romania No interests declared Francisek Drafi Member Slovakia No interests declared Nevenka Trsinar Alternate Slovenia No interests Brodt declared Maria Concepcion Member Spain No interests Prieto Yerro declared Jorge Camarero Alternate Spain No participation entrectinib - Jiménez in final EMEA/H/C/004936 deliberations and MabThera - voting on: EMEA/H/C/000165/II/0162 Baloxavir marboxil -H0004974 Kristina Dunder Member Sweden No interests declared Filip Josephson Alternate Sweden No interests declared Nithyanandan Member United No restrictions Nagercoil Kingdom applicable to this meeting Christian Gartner Co-opted Austria No restrictions member applicable to this meeting Koenraad Norga Co-opted Belgium No participation Temybric Ellipta - member in final EMEA/H/C/005254/WS1683/0 deliberations and 001
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 49/56
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI voting on: Trelegy Ellipta - EMEA/H/C/004363/WS1683/0 010 Jan Co-opted Germany No interests Mueller-Berghaus member declared Blanka Co-opted Czech No interests Hirschlerova member Republic declared Sol Ruiz Co-opted Spain No interests member declared Valerie Lescrainier Expert in Belgium No interests person* declared Danica Juričić Expert in Croatia No interests Nahal person* declared Doris Johanna Expert in Denmark No interests Hovgaard person* declared Henrik Dahllof Expert in Denmark No restrictions person* applicable to this meeting Mette Tranholm Expert in Denmark No interests person* declared Benedicte Hay Expert in France No interests person* declared Isabel Araujo Expert in France No restrictions Fernandez person* applicable to this meeting Nicolas Beix Expert in France No interests person* declared Sylvain Gueho Expert in France No interests person* declared Eva Schlosser Expert in Germany No restrictions person* applicable to this meeting Sabine Mayrhofer Expert in Germany No interests person* declared Michele O'Brien Patient Ireland No restrictions Representative applicable to this in person meeting Jan Welink Expert in Netherlands No interests person* declared Jeroen Koomen Expert in Netherlands No interests person* declared Joost Hagemeijer Expert in Netherlands No interests person* declared Mark van Bussel Expert in Netherlands No interests person* declared Martijn van Gils Expert in Netherlands No interests person* declared Patrick Vrijlandt Expert in Netherlands No interests person* declared Viktoriia Expert in Netherlands No restrictions Starokozhko person* applicable to this meeting Yvonne Krul Poel Expert in Netherlands No restrictions person* applicable to this meeting
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 50/56
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI Anja Schiel Expert in Norway No interests person* declared Fabrice Expert in Norway No restrictions Eroukhmanoff person* applicable to this meeting Alfredo Expert in Spain No interests García-Arieta person* declared Carolina Prieto Expert in Spain No interests Fernandez person* declared María Isabel García Expert in Spain No interests Gallego person* declared Milena Peraita Expert in Spain No interests Ezcurra person* declared Helena Back Expert in Sweden No interests person* declared Marina Senek Expert in Sweden No interests person* declared Tom Meyerson Expert in Sweden No restrictions Goldschmidt person* applicable to this meeting Aldana Rosso Expert via Denmark No interests telephone* declared Louise F. Expert via Denmark No interests Bang-Lauritsen telephone* declared Johanna Expert via Finland No interests Lähteenvuo telephone* declared Karri Penttilä Expert via Finland No interests telephone* declared Kirsti Villikka Expert via Finland No interests telephone* declared Maija Kaukonen Expert via Finland No interests telephone* declared Mona Expert via France No interests Kassem-Youssef telephone* declared Martina Expert via Germany No interests Schussler-Lenz telephone* declared Susanne Expert via Germany No interests Brendler-Schwaab telephone* declared Szabina Papp Expert via Hungary No interests telephone* declared Mair Powell Expert via Ireland No interests telephone* declared Paolo Foggi Expert via Italy No interests telephone* declared Zane Neikena Expert via Latvia No interests telephone* declared Jessica van Expert via Netherlands No interests Montfoort telephone* declared Susan Uiterwaal Expert via Netherlands No interests telephone* declared Ingebjørg Expert via Norway No interests Buajordet telephone* declared Kristin Thorseng Expert via Norway No interests Kvande telephone* declared Macarena Expert via Spain No interests
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 51/56
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI Rodriguez telephone* declared Mendizabal Kristian Expert via Sweden No interests Wennmalm telephone* declared Carole Walker Patient United No interests Representative Kingdom declared via telephone* Berthels Nele Expert via Belgium No interests Adobe* declared Dirix Violette Expert via Belgium No interests Adobe* declared Haelterman Expert via Belgium No interests Edwige Adobe* declared Hue Didier Expert via Belgium No interests Adobe* declared Adriana Andric Expert via Croatia No interests Adobe* declared Nikica Mirošević Expert via Croatia No interests Skvrce Adobe* declared Selma Arapovic Expert via Croatia No interests Dzakula Adobe* declared Anneli Lauhio Expert via Finland No interests Adobe* declared Antero Kallio Expert via Finland No restrictions Adobe* applicable to this meeting Eeva Sofia Expert via Finland No interests Leinonen Adobe* declared Johanna Expert via Finland No interests Lähteenvuo Adobe* declared Juha Kolehmainen Expert via Finland No interests Adobe* declared Katriina Tarkiainen Expert via Finland No interests Adobe* declared Liisa Pylkkänen Expert via Finland No interests Adobe* declared Olli Tenhunen Expert via Finland No interests Adobe* declared Adrien Inoubli Expert via France No interests Adobe* declared George Aislaitner Expert via Germany No interests Adobe* declared Karoline Buhre Expert via Germany No restrictions Adobe* applicable to this meeting Liana Expert via Netherlands No interests Gross-Martirosyan Adobe* declared Maja Sommerfelt Expert via Norway No restrictions Grønvold Adobe* applicable to this meeting Torny Kaasbøll Expert via Norway No interests Adobe* declared Tove Lill Stendal Expert via Norway No interests Adobe* declared Blanca Expert via Spain No interests
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 52/56
Name Role Member Outcome Topics on agenda for which State or restriction restrictions apply affiliation following evaluation of e-DoI Garcia-Ochoa Adobe* declared Macarena Expert via Spain No interests Rodriguez Adobe* declared Mendizabal Rosalía Ruano Expert via Spain No interests Camps Adobe* declared Elina Rönnemaa Expert via Sweden No interests Adobe* declared David Brown Expert via United No interests Adobe* Kingdom declared John Johnston Expert via United No interests Adobe* Kingdom declared Khadija Rantell Expert via United No interests Adobe* Kingdom declared Shirley Hopper Expert via United No interests Adobe* Kingdom declared Meeting run with the help of EMA staff
*Experts were only evaluated against the product(s) they have been invited to talk about.
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 53/56
17. Explanatory notes
The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.
Oral explanations (section 2)
The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.
Initial applications (section 3)
This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.
Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.
The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:
The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (Day 180 List of outstanding issues) and 3.3 (Day 120 list of questions).
CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, update on ongoing new applications for centralised procedures.
The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, products in the decision making phase.
Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)
Extensions of marketing authorisations are applications for the change or addition of new strengths,
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 54/56
formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).
Type II variations - Extension of indication procedures (section 5)
Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.
Ancillary medicinal substances in medical devices (section 6)
Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.
Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)
This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.
Re-examination procedures (section5.3)
This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.
Withdrawal of application (section 3.7)
Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.
Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)
Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.
Pre-submission issues (section 8)
In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.
Post-authorisation issues (section 9)
This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.
Referral procedures (section 10)
This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 55/56
medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.
Pharmacovigilance issues (section 11)
This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.
Inspections Issues (section 12)
This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).
Innovation task force (section 13)
The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.
Scientific advice working party (SAWP) (section 14.3.1)
This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.
Satellite groups / other committees (section 14.2)
This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).
Invented name issues (section 14.3)
This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.
More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/
Committee for medicinal products for human use (CHMP) EMA/CHMP/653549/2019 Page 56/56
20 December 2019 EMA/CHMP/653553/2019
Annex to 14-17 October 2019 CHMP Minutes Pre submission and post authorisations issues
A. PRE SUBMISSION ISSUES ...... 3 A.1. ELIGIBILITY REQUESTS ...... 3 A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications ...... 3 A.3. PRE-SUBMISSION ISSUES FOR INFORMATION ...... 3 B. POST-AUTHORISATION PROCEDURES OUTCOMES ...... 3 B.1. Annual re-assessment outcomes ...... 3 B.1.1. Annual reassessment for products authorised under exceptional circumstances ...... 3 B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES ...... 4 B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal ...... 4 B.2.2. Renewals of Marketing Authorisations for unlimited validity ...... 4 B.2.3. Renewals of Conditional Marketing Authorisations ...... 5 B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES...... 6 B.4. EPARs / WPARs ...... 10 B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES ...... 11 B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects ...... 11 B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects ...... 14 B.5.3. CHMP-PRAC assessed procedures ...... 22 B.5.4. PRAC assessed procedures ...... 31 B.5.5. CHMP-CAT assessed procedures ...... 38 B.5.6. CHMP-PRAC-CAT assessed procedures ...... 39 B.5.7. PRAC assessed ATMP procedures ...... 39 B.5.8. Unclassified procedures and worksharing procedures of type I variations ...... 39 B.5.9. Information on withdrawn type II variation / WS procedure ...... 40 B.5.10. Information on type II variation / WS procedure with revised timetable ...... 42 B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION ...... 42 B.6.1. Start of procedure for New Applications: timetables for information ...... 42 B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information ...... 43 B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information ...... 44
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged.
B.6.4. Annual Re-assessments: timetables for adoption ...... 46 B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed ...... 46 B.6.6. VARIATIONS – START OF THE PROCEDURE ...... 46 B.6.7. Type II Variations scope of the Variations: Extension of indication ...... 46 B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects ...... 46 B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects ...... 48 B.6.10. CHMP-PRAC assessed procedures ...... 55 B.6.11. PRAC assessed procedures ...... 59 B.6.12. CHMP-CAT assessed procedures ...... 64 B.6.13. CHMP-PRAC-CAT assessed procedures ...... 64 B.6.14. PRAC assessed ATMP procedures ...... 64 B.6.15. Unclassified procedures and worksharing procedures of type I variations ...... 64 B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY ...... 66 B.7.1. Yearly Line listing for Type I and II variations ...... 66 B.7.2. Monthly Line listing for Type I variations ...... 66 B.7.3. Opinion on Marketing Authorisation transfer (MMD only) ...... 66 B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) ...... 66 B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) ...... 66 B.7.6. Notifications of Type I Variations (MMD only) ...... 66 C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) ...... 66 D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) ...... 66 E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES ...... 66 E.1. PMF Certification Dossiers:...... 66 E.1.1. Annual Update ...... 66 E.1.2. Variations: ...... 66 E.1.3. Initial PMF Certification: ...... 66 E.2. Time Tables – starting & ongoing procedures: For information ...... 66 F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver ...... 67 F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended ...... 67 F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health ...... 67 G. ANNEX G ...... 67 G.1. Final Scientific Advice (Reports and Scientific Advice letters): ...... 67 G.2. Ongoing procedures ...... 67 G.3. PRIME ...... 67 G.3.1. List of procedures concluding at 14-17 October 2019 CHMP plenary: ...... 67 G.3.2. List of procedures starting in October 2019 for November 2019 CHMP adoption of outcomes ...... 67
EMA/CHMP/653553/2019 Page 2/67
H. ANNEX H - Product Shared Mailboxes – e-mail address ...... 67
A. PRE SUBMISSION ISSUES
A.1. ELIGIBILITY REQUESTS
Report on Eligibility to Centralised Procedure for Adopted October 2019: For adoption
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications
Final Outcome of Rapporteurship allocation for Adopted October 2019: For adoption
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION
Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.
B. POST-AUTHORISATION PROCEDURES OUTCOMES
B.1. Annual re-assessment outcomes
B.1.1. Annual reassessment for products authorised under exceptional circumstances
Atriance - nelarabine - Positive Opinion adopted by consensus together EMEA/H/C/000752/S/0048 with the CHMP assessment report. Novartis Europharm Limited, Rapporteur: Sinan The Marketing Authorisation remains under B. Sarac, PRAC Rapporteur: Hans Christian exceptional circumstances. Siersted The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
Chenodeoxycholic acid Leadiant - Positive Opinion adopted by consensus together chenodeoxycholic acid - with the CHMP assessment report. EMEA/H/C/004061/S/0010, Orphan The Marketing Authorisation remains under Leadiant GmbH, Rapporteur: Konstantinos exceptional circumstances. Markopoulos, PRAC Rapporteur: Adam Przybylkowski The Icelandic and Norwegian CHMP Members Request for Supplementary Information adopted were in agreement with the CHMP opinion. on 25.07.2019.
Qarziba - dinutuximab beta - Positive Opinion adopted by consensus together EMEA/H/C/003918/S/0016, Orphan with the CHMP assessment report. EUSA Pharma (Netherlands) B.V., Rapporteur: The Marketing Authorisation remains under Paula Boudewina van Hennik, PRAC Rapporteur: exceptional circumstances. Brigitte Keller-Stanislawski The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
EMA/CHMP/653553/2019 Page 3/67
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal
Sivextro - tedizolid phosphate - Request for supplementary information adopted EMEA/H/C/002846/R/0031 with a specific timetable. Merck Sharp & Dohme B.V., Rapporteur: Bruno
Sepodes, Co-Rapporteur: Filip Josephson, PRAC
Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted on 17.10.2019, 19.09.2019.
B.2.2. Renewals of Marketing Authorisations for unlimited validity
Akynzeo - fosnetupitant / netupitant / Request for supplementary information adopted palonosetron - EMEA/H/C/003728/R/0024 with a specific timetable. Helsinn Birex Pharmaceuticals Limited, Rapporteur: Peter Kiely, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ilaria Baldelli Request for Supplementary Information adopted on 17.10.2019.
Cerdelga - eliglustat - Positive Opinion adopted by consensus together EMEA/H/C/003724/R/0022, Orphan with the CHMP assessment report and translation Genzyme Europe BV, Rapporteur: Johann timetable. Lodewijk Hillege, Co-Rapporteur: Martina Weise, Based on the review of the available information, PRAC Rapporteur: Eva A. Segovia the CHMP was of the opinion that the renewal of Request for Supplementary Information adopted the marketing authorisation can be granted with on 25.07.2019. unlimited validity.
The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Kengrexal - cangrelor - Positive Opinion adopted by consensus together EMEA/H/C/003773/R/0020 with the CHMP assessment report and translation Chiesi Farmaceutici S.p.A., Rapporteur: Johann timetable. Lodewijk Hillege, Co-Rapporteur: Alar Irs, PRAC Based on the review of the available information, Rapporteur: Ilaria Baldelli the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Quinsair - levofloxacin - Request for supplementary information adopted EMEA/H/C/002789/R/0022 with a specific timetable. Chiesi Farmaceutici S.p.A., Rapporteur: Ondřej Slanař, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon Request for Supplementary Information adopted
EMA/CHMP/653553/2019 Page 4/67
on 17.10.2019.
Saxenda - liraglutide - Positive Opinion adopted by consensus together EMEA/H/C/003780/R/0024 with the CHMP assessment report and translation Novo Nordisk A/S, Rapporteur: Johann Lodewijk timetable. Hillege, Co-Rapporteur: Sinan B. Sarac, PRAC Based on the review of the available information, Rapporteur: Menno van der Elst the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
B.2.3. Renewals of Conditional Marketing Authorisations
Caprelsa - vandetanib - Request for supplementary information adopted EMEA/H/C/002315/R/0041 with a specific timetable. Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni Request for Supplementary Information adopted on 17.10.2019.
CRYSVITA - burosumab - Positive Opinion adopted by consensus together EMEA/H/C/004275/R/0009, Orphan with the CHMP assessment report. Kyowa Kirin Holdings B.V., Rapporteur: Kristina The CHMP was of the opinion that the renewal for Dunder, Co-Rapporteur: Jayne Crowe, PRAC this conditional Marketing Authorisation can be Rapporteur: Brigitte Keller-Stanislawski granted.
The Marketing Authorisation remains conditional.
The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Holoclar - ex vivo expanded autologous Request for supplementary information adopted human corneal epithelial cells containing with a specific timetable. stem cells - EMEA/H/C/002450/R/0026, Orphan, ATMP Chiesi Farmaceutici S.p.A., Rapporteur: Egbert Flory, Co-Rapporteur: Paolo Gasparini, CHMP Coordinators: Jan Mueller-Berghaus and Daniela Melchiorri, PRAC Rapporteur: Rhea Fitzgerald Request for Supplementary Information adopted on 11.10.2019.
OCALIVA - obeticholic acid - See 9.1 EMEA/H/C/004093/R/0018, Orphan Request for supplementary information adopted Intercept Pharma International Limited, with a specific timetable. Rapporteur: Jorge Camarero Jiménez, PRAC
Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 19.09.2019.
EMA/CHMP/653553/2019 Page 5/67
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES
Signal detection Adopted. PRAC recommendations on signals adopted at the PRAC meeting held on 30. September – 3 October 2019 PRAC:
Signal of myasthenia gravis:
Imfinzi - Durvalumab – EMEA/H/C/004771
Rapporteur: Sinan B Sarac, Co-Rapporteur: Jorge Camarero Jimenez
PRAC recommendation on a variation
Action: For adoption
PSUR procedures for which PRAC adopted a Adopted. recommendation for variation of the terms of the MA at its October 2019 meeting:
EMEA/H/C/PSUSA/00000944/201902 The CHMP, having considered in accordance with (degarelix) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Firmagon (EMEA/H/C/000986) (degarelix), and the PRAC assessment report as appended the Ferring Pharmaceuticals A/S, Rapporteur: variation to the terms of the marketing Alexandre Moreau, PRAC Rapporteur: Ghania authorisation(s) for the above mentioned Chamouni, “From: 17/02/2016 To: 17/02/2019” medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reaction rhabdomyolysis with a
frequency rare. The Package leaflet is updated
accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned
recommendation of the CHMP. EMEA/H/C/PSUSA/00001393/201902 The CHMP, having considered in accordance with (fingolimod) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Gilenya (EMEA/H/C/002202) (fingolimod), and the PRAC assessment report as appended, Novartis Europharm Limited, Rapporteur: recommends by consensus, the variation to the Alexandre Moreau, PRAC Rapporteur: Ghania terms of the marketing authorisation(s) for the Chamouni, “01/03/2018 To: 28/02/2019” above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning on lymphoma and PML. The Package leaflet section 2 is updated accordingly. Update of section 4.8 of the SmPC to add ‘autoimmune haemolytic anaemia’ with a frequency “not known” and ‘weight decreased’
EMA/CHMP/653553/2019 Page 6/67
with a frequency “common”. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00002059/201903 The CHMP, having considered in accordance with (mifamurtide) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Mepact (EMEA/H/C/000802) (mifamurtide), and the PRAC assessment report as appended, Takeda France SAS, Rapporteur: Johann recommends by consensus, the variation to the Lodewijk Hillege, PRAC Rapporteur: Menno van terms of the marketing authorisation(s) for the der Elst, “Period Covered From: 04/03/2016 To: above mentioned medicinal product(s), 04/03/2019” concerning the following change(s): Updated of section 4.8 of the SmPC to add ‘pericardial effusion’ as an ADR in section 4.8 under SOC Cardiac disorders; a frequency of ‘not known (cannot be estimated from available data)’ is considered appropriate. The Package Leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00009200/201903 The CHMP, having considered in accordance with (ipilimumab) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Yervoy (EMEA/H/C/002213) (ipilimumab), and the PRAC assessment report as appended, Bristol-Myers Squibb Pharma EEIG, Rapporteur: recommends by consensus, the variation to the Paula Boudewina van Hennik, PRAC Rapporteur: terms of the marketing authorisation(s) for the Menno van der Elst, “From: 23/03/2018 To: above mentioned medicinal product(s), 23/03/2019” concerning the following change(s): Update of section 4.4 of the SmPC to add transient vision loss as a potential consequence of ipilimumab related ocular inflammations and of section 4.8 of the SmPC to add the adverse drug reaction serous retinal detachment with a rare frequency; a consequential minor change is also made to section 4.4 of the SmPC. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010182/201903 The CHMP, having considered in accordance with (cholic acid (CTX, AMACR or cholesterol Article 28 of Regulation (EC) No 726/2004 the 7α-hydroxylase deficiency indication)) PSUR on the basis of the PRAC recommendation CAPS: and the PRAC assessment report as appended Kolbam (EMEA/H/C/002081) (cholic acid), recommends by consensus the variation to the Retrophin Europe Ltd, Rapporteur: Konstantinos terms of the marketing authorisation(s) for the Markopoulos, PRAC Rapporteur: Agni Kapou, above mentioned medicinal product(s), “From: 17/03/2018 To: 17/03/2019” concerning the following change(s):
EMA/CHMP/653553/2019 Page 7/67
Update of section 4.2 and 4.4 of the SmPC in order to add a warning on the risk of hepatotoxicity with the use of cholic acid and extending the need for close monitoring and stopping rules to patients with pre-existing hepatic impairment related to the primary disease. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010368/201903 The CHMP, having considered in accordance with (oritavancin) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Orbactiv (EMEA/H/C/003785) (oritavancin), and the PRAC assessment report as appended, Menarini International Operations Luxembourg recommends by consensus, the variation to the S.A., Rapporteur: Janet Koenig, PRAC terms of the marketing authorisation(s) for the Rapporteur: Adam Przybylkowski, “From: above mentioned medicinal product(s), 20/09/2018 To: 19/03/2019” concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add a warning on the risk of anaphylactic reactions, including anaphylactic shock and to add anaphylactic reaction as a possible adverse reaction with a frequency “uncommon” and anaphylactic shock with the frequency “unknown”. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010662/201903 The CHMP, having considered in accordance with (ocrelizumab) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Ocrevus (EMEA/H/C/004043) (ocrelizumab), and the PRAC assessment report as appended, Roche Registration GmbH, Rapporteur: Mark recommends by consensus, the variation to the Ainsworth, PRAC Rapporteur: Brigitte terms of the marketing authorisation(s) for the Keller-Stanislawski, “From: 27/09/2018 To: above mentioned medicinal product(s), 27/03/2019” concerning the following change(s): Update of section 4.4 of the SmPC to revise the warning on the risk of hepatitis B reactivation. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010733/201903 The CHMP, having considered in accordance with (galcanezumab) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Emgality (EMEA/H/C/004648) (galcanezumab), and the PRAC assessment report as appended, Eli Lilly Nederland B.V., Rapporteur: Daniela recommends by consensus, the variation to the Melchiorri, PRAC Rapporteur: Kirsti Villikka, terms of the marketing authorisation(s) for the
EMA/CHMP/653553/2019 Page 8/67
“Period Covered From: 26/09/2018 To: above mentioned medicinal product(s), 26/03/2019” concerning the following change(s): Update of section 4.8 of the SmPC to add anaphylaxis and angioedema with a frequency rare and rash with a frequency common, and to add information to section 4.4 that serious hypersensitivity reactions including cases of anaphylaxis, angioedema and urticarial have been reported. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010753/201903 The CHMP, having considered in accordance with (naldemedine) Article 28 of Regulation (EC) No 726/2004 the CAPS: PSUR on the basis of the PRAC recommendation Rizmoic (EMEA/H/C/004256) (naldemedine), and the PRAC assessment report as appended Shionogi B.V., Rapporteur: Mark Ainsworth, recommends by consensus the variation to the PRAC Rapporteur: Rhea Fitzgerald, “21/09/2018 terms of the marketing authorisation(s) for the To: 21/03/2019” above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 of the SmPC to reflect that cases of gastrointestinal perforation have been reported in post-marketing setting, including fatal cases, when naldemedine was used in patients who were at an increased risk of gastrointestinal perforation. Naldemedine must not be used in patients with known or suspected gastrointestinal obstruction or in patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation. Section 4.8 is updated to add gastrointestinal perforation with a frequency “Not known”. The package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00003098/201903 The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and (vardenafil) Article 107g(3) of Directive 2001/83/EC the PSUR CAPS: on the basis of the PRAC recommendation and the PRAC assessment report as appended, Levitra (EMEA/H/C/000475) (vardenafil), Bayer recommends by consensus, the variation to the AG, Rapporteur: Maria Concepcion Prieto Yerro, terms of the marketing authorisation(s) for the PRAC Rapporteur: Maria del Pilar Rayon medicinal products containing the above referred Vivanza (EMEA/H/C/000488) (vardenafil), active substance(s), concerning the following Bayer AG, Rapporteur: Maria Concepcion Prieto change(s): Yerro, PRAC Rapporteur: Maria del Pilar Rayon, Update of section 4.8 of the SmPC to delete the “04/03/2016 To: 04/03/2019” paragraph on vascular disorders, and include the safety data in the tabulated list of adverse drug
EMA/CHMP/653553/2019 Page 9/67
reactions and update of section 4.4 of the SmPC to add a warning regarding vascular disorders. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
B.4. EPARs / WPARs
Arsenic trioxide Accord - arsenic trioxide - For information only. Comments can be sent to EMEA/H/C/005175 the PL in case necessary. Accord Healthcare S.L.U., treatment of relapsed acute promyelocytic leukaemia (APL), Generic, Generic of Trisenox, Generic application (Article 10(1) of Directive No 2001/83/EC)
Bortezomib Fresenius Kabi - bortezomib - For information only. Comments can be sent to EMEA/H/C/005074 the PL in case necessary. Fresenius Kabi Deutschland GmbH, treatment of multiple myeloma, Generic, Generic of VELCADE, Generic application (Article 10(1) of Directive No 2001/83/EC)
Ivozall - clofarabine - EMEA/H/C/005039 For information only. Comments can be sent to ORPHELIA Pharma SAS, treatment of acute the PL in case necessary. lymphoblastic leukaemia, Generic, Generic of Evoltra, Generic application (Article 10(1) of Directive No 2001/83/EC)
Nuzyra - omadacycline - For information only. Comments can be sent to EMEA/H/C/004715 the PL in case necessary. Paratek Ireland Limited, treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults, New active substance (Article 8(3) of Directive No 2001/83/EC) WPAR
Qtrilmet - metformin hydrochloride / For information only. Comments can be sent to saxagliptin / dapagliflozin - the PL in case necessary. EMEA/H/C/004910 AstraZeneca AB, - to improve glycaemic control when metformin with or without sulphonylurea (SU) does not provide adequate glycaemic control and where simultaneous addition of dapagliflozin and saxagliptin is considered necessary - to improve glycaemic control when metformin with or without sulphonylurea (SU) and either dapagliflozin or saxagliptin does not provide adequate glycaemic control - when already being treated with dapagliflozin and
EMA/CHMP/653553/2019 Page 10/67
saxagliptin and metformin., Fixed combination application (Article 10b of Directive No 2001/83/EC)
Rhokiinsa - netarsudil - EMEA/H/C/004583 For information only. Comments can be sent to Aerie Pharmaceuticals Ireland Ltd, indicated for the PL in case necessary. the reduction of elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension., New active substance (Article 8(3) of Directive No 2001/83/EC)
Senstend - lidocaine / prilocaine - For information only. Comments can be sent to EMEA/H/C/005298 the PL in case necessary. Plethora Pharma Solutions Limited, treatment of primary premature ejaculation, Informed Consent of Fortacin, Informed consent application (Article 10c of Directive No 2001/83/EC)
XOSPATA - gilteritinib - For information only. Comments can be sent to EMEA/H/C/004752, Orphan the PL in case necessary. Astellas Pharma Europe B.V., treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, New active substance (Article 8(3) of Directive No 2001/83/EC)
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES
Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects
Accofil - filgrastim - Positive Opinion adopted by consensus on EMEA/H/C/003956/II/0034/G 17.10.2019. The Icelandic and Norwegian CHMP Accord Healthcare S.L.U., Rapporteur: Outi Members were in agreement with the CHMP Mäki-Ikola recommendation. Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 12.09.2019.
AMGEVITA - adalimumab - Positive Opinion adopted by consensus on EMEA/H/C/004212/II/0019/G 26.09.2019. The Icelandic and Norwegian CHMP Amgen Europe B.V., Rapporteur: Kristina Dunder Members were in agreement with the CHMP Opinion adopted on 26.09.2019. recommendation.
Bexsero - meningococcal group B vaccine Positive Opinion adopted by consensus on (recombinant, component, adsorbed) - 10.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/002333/II/0079/G Members were in agreement with the CHMP GSK Vaccines S.r.l, Rapporteur: Kristina Dunder recommendation. Opinion adopted on 10.10.2019.
EMA/CHMP/653553/2019 Page 11/67
Cimzia - certolizumab pegol - Positive Opinion adopted by consensus on EMEA/H/C/001037/II/0079/G 26.09.2019. The Icelandic and Norwegian CHMP UCB Pharma S.A., Rapporteur: Kristina Dunder Members were in agreement with the CHMP Opinion adopted on 26.09.2019. recommendation. Request for Supplementary Information adopted on 11.07.2019.
Cresemba - isavuconazole - Positive Opinion adopted by consensus on EMEA/H/C/002734/II/0024/G, Orphan 26.09.2019. The Icelandic and Norwegian CHMP Basilea Pharmaceutica Deutschland GmbH, Members were in agreement with the CHMP Rapporteur: Johann Lodewijk Hillege recommendation. Opinion adopted on 26.09.2019.
Dupixent - dupilumab - Positive Opinion adopted by consensus on EMEA/H/C/004390/II/0018/G 17.10.2019. The Icelandic and Norwegian CHMP sanofi-aventis groupe, Rapporteur: Jan Members were in agreement with the CHMP Mueller-Berghaus recommendation. Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 12.09.2019, 25.07.2019.
Empliciti - elotuzumab - Positive Opinion adopted by consensus on EMEA/H/C/003967/II/0019/G 03.10.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Members were in agreement with the CHMP Paula Boudewina van Hennik recommendation. Opinion adopted on 03.10.2019.
Empliciti - elotuzumab - Positive Opinion adopted by consensus on EMEA/H/C/003967/II/0020/G 10.10.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Members were in agreement with the CHMP Paula Boudewina van Hennik recommendation. Opinion adopted on 10.10.2019.
Erelzi - etanercept - Positive Opinion adopted by consensus on EMEA/H/C/004192/II/0018 26.09.2019. The Icelandic and Norwegian CHMP Sandoz GmbH, Rapporteur: Johann Lodewijk Members were in agreement with the CHMP Hillege recommendation. Opinion adopted on 26.09.2019. Request for Supplementary Information adopted on 11.07.2019.
GONAL-f - follitropin alfa - Request for supplementary information adopted EMEA/H/C/000071/II/0145/G with a specific timetable. Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 10.10.2019.
Kevzara - sarilumab - Positive Opinion adopted by consensus on EMEA/H/C/004254/II/0015/G 17.10.2019. The Icelandic and Norwegian CHMP sanofi-aventis groupe, Rapporteur: Jan Members were in agreement with the CHMP Mueller-Berghaus recommendation. Opinion adopted on 17.10.2019.
EMA/CHMP/653553/2019 Page 12/67
LIBTAYO - cemiplimab - Positive Opinion adopted by consensus on EMEA/H/C/004844/II/0002/G 17.10.2019. The Icelandic and Norwegian CHMP Regeneron Ireland Designated Activity Company Members were in agreement with the CHMP (DAC), Rapporteur: Sinan B. Sarac recommendation. Opinion adopted on 17.10.2019.
Mozobil - plerixafor - Request for supplementary information adopted EMEA/H/C/001030/II/0040/G, Orphan with a specific timetable. Genzyme Europe BV, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 17.10.2019.
NeuroBloc - botulinum toxin type B - Request for supplementary information adopted EMEA/H/C/000301/II/0104/G with a specific timetable. Sloan Pharma S.a.r.l, Rapporteur: Bruno Sepodes Request for Supplementary Information adopted on 26.09.2019.
NovoSeven - eptacog alfa (activated) - Positive Opinion adopted by consensus on EMEA/H/C/000074/II/0106 17.10.2019. The Icelandic and Norwegian CHMP Novo Nordisk A/S, Rapporteur: Paula Boudewina Members were in agreement with the CHMP van Hennik recommendation. Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 06.06.2019, 07.03.2019, 20.09.2018.
Pelgraz - pegfilgrastim - Positive Opinion adopted by consensus on EMEA/H/C/003961/II/0011/G 17.10.2019. The Icelandic and Norwegian CHMP Accord Healthcare S.L.U., Rapporteur: Sol Ruiz Members were in agreement with the CHMP Opinion adopted on 17.10.2019. recommendation. Request for Supplementary Information adopted on 12.09.2019.
Privigen - human normal immunoglobulin - Request for supplementary information adopted EMEA/H/C/000831/II/0154/G with a specific timetable. CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 26.09.2019.
Repaglinide Accord - repaglinide - Request for supplementary information adopted EMEA/H/C/002318/II/0009/G with a specific timetable. Accord Healthcare S.L.U., Generic, Generic of NovoNorm, Rapporteur: Melinda Sobor Request for Supplementary Information adopted on 10.10.2019, 26.04.2019.
Semglee - insulin glargine - Positive Opinion adopted by consensus on EMEA/H/C/004280/II/0009 26.09.2019. The Icelandic and Norwegian CHMP Mylan S.A.S, Rapporteur: Martina Weise Members were in agreement with the CHMP Opinion adopted on 26.09.2019. recommendation. Request for Supplementary Information adopted
EMA/CHMP/653553/2019 Page 13/67
on 17.01.2019.
Simulect - basiliximab - Request for supplementary information adopted EMEA/H/C/000207/II/0101/G with a specific timetable. Novartis Europharm Limited, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 10.10.2019. Letter from the applicant dated 14.10.2019 requesting a clock stop extension. For adoption
Viramune - nevirapine - Request for supplementary information adopted EMEA/H/C/000183/II/0141/G with a specific timetable. Boehringer Ingelheim International GmbH, Rapporteur: Bruno Sepodes Request for Supplementary Information adopted on 10.10.2019.
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects
Afstyla - lonoctocog alfa - Request for supplementary information adopted EMEA/H/C/004075/II/0024 with a specific timetable. CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.4 and 4.8 of the SmPC with safety information regarding the development of factor VIII inhibitors in patients treated with Afstyla based on clinical trial and post-marketing data reviewed recently with data lock point 03 January 2019. The PL is updated accordingly. Additionally, local representatives' details for Bulgaria and Croatia have been updated.” Request for Supplementary Information adopted on 10.10.2019.
Atriance - nelarabine - Positive Opinion adopted by consensus on EMEA/H/C/000752/II/0046/G 17.10.2019. The Icelandic and Norwegian CHMP Novartis Europharm Limited, Rapporteur: Sinan Members were in agreement with the CHMP B. Sarac, PRAC Rapporteur: Hans Christian recommendation. Siersted, “Update of Annex II to remove the existing specific obligation Study NLR506AUS02T 'Intensified methotrexate, nelarabine and augmented BFM therapy for children and young adults with newly diagnosed T-ALL and T-LBL'; a new SOB is introduced in Annex II to provide yearly updates on any new information concerning the efficacy and safety of the product in the approved indication. Additionally, section 4.6 of the SmPC is updated in order to revise information on the male and female contraception taking into consideration available
EMA/CHMP/653553/2019 Page 14/67
non-clinical and clinical safety data as well as internal MAH's guidelines based on information from literature, health authority and working group guidelines. Minor corrections are also made to sections 4.8 and 5.3 of the SmPC. Moreover, the MAH took the opportunity to update details of the local representatives in the PL and introduce minor editorial changes in the PI. The revised RMP version 10.1 has been agreed.” Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 25.07.2019, 28.02.2019.
Baraclude - entecavir - Request for supplementary information adopted EMEA/H/C/000623/II/0063 with a specific timetable. Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson, “Submission of responses to the final clinical study report (CSR) from a Paediatric Safety and Efficacy Study (AI463189), a comparative study of the antiviral efficacy and safety of Entecavir (ETV) versus placebo in paediatric subjects with chronic Hepatitis B Virus (HBV) infection who are HBeAg positive, in order to provide additional clarification regarding the on-treatment and long-term follow-up haematology findings. The final CSR for AI463189 was already submitted and assessed within the context of procedure EMEA/H/C/000623/P46/010.” Request for Supplementary Information adopted on 10.10.2019.
CRYSVITA - burosumab - Positive Opinion adopted by consensus on EMEA/H/C/004275/II/0004, Orphan 17.10.2019. The Icelandic and Norwegian CHMP Kyowa Kirin Holdings B.V., Rapporteur: Kristina Members were in agreement with the CHMP Dunder, “Update of sections 4.2, 4.8, 5.1 and 5.2 recommendation. of the SmPC, to reflect the results of Study UX023-CL301, a phase III study undertaken to further assess the efficacy, safety and pharmacodynamics in paediatric patients aged 1-12 years with X-linked Hypophosphataemia (XLH). The provision of the final CSR addresses Specific Obligation 2 (ANX 002). The Package Leaflet and Annex II have been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC to increase readability.” Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 27.06.2019.
Empliciti - elotuzumab - Positive Opinion adopted by consensus on
EMA/CHMP/653553/2019 Page 15/67
EMEA/H/C/003967/II/0018 26.09.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Members were in agreement with the CHMP Paula Boudewina van Hennik, “Update of section recommendation. 5.1 of the SmPC with final overall survival data from study CA204004 (A Phase 3, Randomized, Open Label Trial of lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma).” Opinion adopted on 26.09.2019.
EVOTAZ - atazanavir / cobicistat - Positive Opinion adopted by consensus on EMEA/H/C/003904/II/0030 17.10.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Members were in agreement with the CHMP Bruno Sepodes, “Update of sections 4.3 and 4.5 recommendation. of the SmPC in order to add as contraindications the concomitant administration of dabigatran or lomitapide with Evotaz, and to add recommendations on the drug-drug interaction between Evotaz and the direct oral anticoagulants dabitagran, ticagrelor, apixaban and edoxaban, as well as with the lipid modifying agent lomitapide, based on already updated information in other marketing authorisations. Sections 4.2, 4.4 and 4.6 of the SmPC are also updated to reflect the accumulated information on the use of cobicistat during pregnancy, based on published literature. The Package Leaflet is updated accordingly. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.” Opinion adopted on 17.10.2019.
Glivec - imatinib - Request for supplementary information adopted EMEA/H/C/000406/II/0117 with a specific timetable. Novartis Europharm Limited, Rapporteur: Jorge Camarero Jiménez, “Update of section 4.6 of the SmPC to include that women of childbearing potential must be advised to use effective contraception for at least 15 days after stopping treatment with imatinib, based on a company review of the company Core Data Sheet. The PL has been updated accordingly.” Request for Supplementary Information adopted on 10.10.2019.
Herzuma - trastuzumab - Positive Opinion adopted by consensus on EMEA/H/C/002575/II/0023 10.10.2019. The Icelandic and Norwegian CHMP Celltrion Healthcare Hungary Kft., Rapporteur: Members were in agreement with the CHMP Jan Mueller-Berghaus, “C.I.13: Submission of the recommendation. final report of study CT-P6 3.2; this is a phase 3, double blind, randomized, parallel-group,
EMA/CHMP/653553/2019 Page 16/67
active-controlled study to compare the efficacy and safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant treatment in patients with HER2 positive early breast cancer.” Opinion adopted on 10.10.2019.
Hizentra - human normal immunoglobulin - Request for supplementary information adopted EMEA/H/C/002127/II/0110/G with a specific timetable. CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include the number of PID patients, to include prescriber information and tolerability information for manual push infusion, to update prescriber information on device-assisted infusion and to include safety information, based on final results from study IgPro20_4004, an open-label study to evaluate the safety and tolerability of higher infusion parameters of Hizentra infused manually or with pump assistance in PID patients. Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update the number of PID patients and to include safety information based on final results from study IgPro_4005, a phase 4, open-label, single-sequence, crossover study to investigate the tolerability, safety and efficacy of biweekly Hizentra dosing in PID patients. The Package Leaflet is updated accordingly. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to update the list of local representative in the Package Leaflet, to make some editorial updates in sections 4.2, 5.1 and 5.2 of the SmPC and to bring the PI in line with the latest QRD template version 10.1.” Request for Supplementary Information adopted on 17.10.2019.
IBRANCE - palbociclib - Request for supplementary information adopted EMEA/H/C/003853/II/0016 with a specific timetable. Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update with information following submission of the final results from the pivotal Study A5481023 “A double blind, Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy” listed as a recommendation at the time of initial MA.” Request for Supplementary Information adopted on 26.09.2019, 25.07.2019, 02.05.2019,
EMA/CHMP/653553/2019 Page 17/67
31.01.2019.
Imbruvica - ibrutinib - Request for supplementary information adopted EMEA/H/C/003791/II/0053, Orphan with a specific timetable. Janssen-Cilag International NV, Rapporteur: Filip Josephson, “The submission of final report on PFS by investigator assessment in Study PCYC-1112-CA, including PFS2 and overall survival data until study closure per protocol (ANX_003)” Request for Supplementary Information adopted on 03.10.2019.
Increlex - mecasermin - Positive Opinion adopted by consensus on EMEA/H/C/000704/II/0059 10.10.2019. The Icelandic and Norwegian CHMP Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, Members were in agreement with the CHMP “Submission of the final analysis for the Category recommendation. 3, Additional Pharmacovigilance Activity MEA 020.3, on Lowest Effective Dose for mecasermin. No changes to the SmPC or Patient Leaflet are proposed as part of this final analysis on Lowest Effective Dose of mecasermin.” Opinion adopted on 10.10.2019. Request for Supplementary Information adopted on 16.05.2019.
Instanyl - fentanyl - Positive Opinion adopted by consensus on EMEA/H/C/000959/II/0051 10.10.2019. The Icelandic and Norwegian CHMP Takeda Pharma A/S, Rapporteur: Alexandre Members were in agreement with the CHMP Moreau, “Update of section 4.8 to include recommendation. dyspnoea. The MAH has also taken the opportunity to include editorial changes in Patient Leaflet.” Opinion adopted on 10.10.2019.
Invanz - ertapenem - Positive Opinion adopted by consensus on EMEA/H/C/000389/II/0060 10.10.2019. The Icelandic and Norwegian CHMP Merck Sharp & Dohme B.V., Rapporteur: Bruno Members were in agreement with the CHMP Sepodes, “To update sections 4.8 and 5.1 of the recommendation. SmPC to update the safety information with the addition of a new post-marketing adverse reaction term: acute generalized exanthematous pustulosis (AGEP) and to update the breakpoints table with the most recent EUCAST recommendation (v 9.0, Jan 2019) on clinical breakpoints for ertapenem. Section 4 of the Package Leaflet is updated accordingly. The MAH is also updating the labelling section and the rest of the Product Information according to the latest QRD requirements and is updating List of Local Representatives.” Opinion adopted on 10.10.2019.
EMA/CHMP/653553/2019 Page 18/67
Kyntheum - brodalumab - Positive Opinion adopted by consensus on EMEA/H/C/003959/II/0011 26.09.2019. The Icelandic and Norwegian CHMP LEO Pharma A/S, Rapporteur: Johann Lodewijk Members were in agreement with the CHMP Hillege, “Update of section 5.1 of the SmPC recommendation. “Mechanism of action” subsection with information about the cytokine IL-17C.” Opinion adopted on 26.09.2019. Request for Supplementary Information adopted on 25.07.2019.
MabThera - rituximab - Request for supplementary information adopted EMEA/H/C/000165/II/0165 with a specific timetable. Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Change in the posology section as 8 cycles of MabThera should be used in combination with 6-8 (previously 8) cycles of CHOP chemotherapy.” Request for Supplementary Information adopted on 17.10.2019, 25.07.2019.
Mepsevii - vestronidase alfa - Positive Opinion adopted by consensus on EMEA/H/C/004438/II/0008, Orphan 17.10.2019. The Icelandic and Norwegian CHMP Ultragenyx Germany GmbH, Rapporteur: Johann Members were in agreement with the CHMP Lodewijk Hillege, “Update of section 5.3 of the recommendation. SmPC based on the final results from study UX003-PC010 a Developmental and Perinatal/Postnatal reproduction non-clinical study in rats including a Post-natal Behavioural/Functional Evaluation. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1.” Opinion adopted on 17.10.2019.
Mylotarg - gemtuzumab ozogamicin - Request for supplementary information adopted EMEA/H/C/004204/II/0010/G, Orphan with a specific timetable. Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, “A group of two type II variations, to submit the non-clinical in vitro study reports PFZ-07 and 6000572 relating to the effects of gemtuzumab ozogamicin on platelet development as well as on human platelet function.” Request for Supplementary Information adopted on 10.10.2019.
PREVYMIS - letermovir - Request for supplementary information adopted EMEA/H/C/004536/II/0013, Orphan with a specific timetable. Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update the viral resistance profile that may be associated with a change in susceptibility to letermovir considering new intro
EMA/CHMP/653553/2019 Page 19/67
pharmacology data based on the analysis of the patients’ samples included in the study MK-8228. This study is a Phase III Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV Seropositive Allogeneic Hematopoietic Stem Cell. This variation follows the recommendation dated 9th November 2017 that asked for the submission when available of the results to update the CMV phenotypic resistance analyses of all clinical isolates for subjects failing letermovir treatment and to explore the possibility to obtain additional pre-failure CMV genotypic data from available samples.” Request for Supplementary Information adopted on 17.10.2019.
Xarelto - rivaroxaban - Request for supplementary information adopted EMEA/H/C/000944/II/0068 with a specific timetable. Bayer AG, Rapporteur: Kristina Dunder, “Update of section 5.1, of the SmPC based on results from the pantoprazole/placebo randomization part of the COMPASS study; this is part of a double-blind, double-dummy randomized trial in which pantoprazole is being compared with placebo in patients participating in the trial who are not receiving a proton-pump inhibitor. In addition, an amendment to the COMPASS Clinical Study Report is submitted to correct values caused by a programming error in the statistical outputs in this study. No changes on the approved label are proposed due to this correction.” Request for Supplementary Information adopted on 03.10.2019.
XGEVA - denosumab - Positive Opinion adopted by consensus on EMEA/H/C/002173/II/0069 17.10.2019. The Icelandic and Norwegian CHMP Amgen Europe B.V., Rapporteur: Kristina Members were in agreement with the CHMP Dunder, “Update of SmPC sections 4.2, 4.8, 5.1 recommendation. and 5.2 based on the final analysis from study 20062004; a phase 2, open-label, single-group study to evaluate the safety and pharmacokinetics of denosumab in adult and adolescent subjects with giant cell tumour of bone (GCTB). The final CSR for study 20062004 was previously assessed by CHMP as part of procedure P46 027 and the finalisation of the study addresses the final PIP measure. In addition, the MAH took the opportunity to update
EMA/CHMP/653553/2019 Page 20/67
the description of ONJ incidence in section 4.8 of the SmPC in order to express events per 100 patient years without a percentage sign. The Package Leaflet has been updated accordingly.” Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 14.06.2019.
Zytiga - abiraterone acetate - Request for supplementary information adopted EMEA/H/C/002321/II/0058 with a specific timetable. Janssen-Cilag International NV, Rapporteur: Jorge Camarero Jiménez, “To update section 5.1 of the SmPC based on final results from study PCR3011 (Lattitude); this is a randomized, double-blind, placebo-controlled study designed to determine the efficacy of abiraterone acetate and low-dose prednisone in men with metastatic hormone-naive prostate cancer.” Request for Supplementary Information adopted on 10.10.2019.
WS1636/G See 9.1 Mekinist-EMEA/H/C/002643/WS1636/ Request for supplementary information adopted 0035/G with a specific timetable. Tafinlar-EMEA/H/C/002604/WS1636/
0040/G
Novartis Europharm Limited, Lead Rapporteur:
Filip Josephson, “Update of section 5.1 of the
Mekinist (trametinib) and Tafinlar (dabrafenib)
SmPC to include the 5-years overall survival (OS) results from study MEK115306 (COMBI-d), a phase III, randomised, double-blinded study comparing the combination of dabrafenib and trametinib to dabrafenib and placebo in first-line therapy for subjects with unresectable or metastatic BRAF V600/K mutation-positive cutaneous melanoma and the 5-years overall survival (OS) results from study MEK116513 (COMBI-v), a phase III, open-label, 2 arm, randomised study comparing dabrafenib and trametinib combination therapy with vemurafenib monotherapy in BRAF V600 mutation-positive metastatic melanoma.” Request for Supplementary Information adopted on 03.10.2019.
WS1637 Positive Opinion adopted by consensus on Ebymect-EMEA/H/C/004162/WS1637/ 17.10.2019. The Icelandic and Norwegian CHMP 0039 Members were in agreement with the CHMP Edistride-EMEA/H/C/004161/WS1637/ recommendation. 0032 Forxiga-EMEA/H/C/002322/WS1637/
EMA/CHMP/653553/2019 Page 21/67
0051 Xigduo-EMEA/H/C/002672/WS1637/0050 AstraZeneca AB, Lead Rapporteur: Kristina Dunder, “Update of sections 4.4 (Special warnings and precautions for use) and 4.8 (Undesirable effects) of the SmPC of dapagliflozin-containing products with respect to the Fournier’s gangrene class labelling language, following results from the DECLARE study (a Multicentre, Randomized, Double-Blind, Placebo-Controlled cardiovascular outcome trial in Patients with Type 2 Diabetes). The Package Leaflet is updated accordingly.” Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 27.06.2019.
WS1683 See 9.1 Elebrato Ellipta-EMEA/H/C/004781/ Request for supplementary information adopted WS1683/0012 with a specific timetable. Temybric Ellipta-EMEA/H/C/005254/
WS1683/0001
Trelegy Ellipta-EMEA/H/C/004363/
WS1683/0010
GlaxoSmithKline Trading Services Limited, Lead
Rapporteur: Peter Kiely, “Update of SmPC in order to add information in section 5.1 on survival data from the IMPACT study”
Request for Supplementary Information adopted on 17.10.2019.
B.5.3. CHMP-PRAC assessed procedures
Bydureon - exenatide - Request for supplementary information adopted EMEA/H/C/002020/II/0064 with a specific timetable. AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, “Update of sections 4.2 and 4.4 of the SmPC in order to remove the limitation of use in patients with moderate renal impairment (creatinine clearance [CrCl] 30 to 50 mL/min) based on pooled data from 8 EQW/EQWS studies undertaken in patients with mild renal impairment/chronic kidney disease stage 2 or moderate renal impairment/chronic kidney disease stage 3, and on supportive data from EXSCEL (Study D5551C00003/BCB109) including a subset of patients with moderate renal impairment. In addition, the MAH took the opportunity to introduce GFR as the main indicator of renal
EMA/CHMP/653553/2019 Page 22/67
function rather than CrCl. The Package Leaflet has been updated accordingly and the MAH has taken the opportunity to implement some minor changes in the labelling. An updated RMP version 34 was provided with the application, which includes consequential changes as well as a proposal for the removal of Acute Renal Failure (ARF) as an Important Identified Risk based on the GVP V Rev2 guidance. In addition, upon request following the assessment of II/54, a Pan EU epidemiological study to monitor events of pancreatic cancer has been included as an additional planned pharmacovigilance activity.” Request for Supplementary Information adopted on 17.10.2019.
Eliquis - apixaban - Positive Opinion adopted by consensus on EMEA/H/C/002148/II/0063 03.10.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Members were in agreement with the CHMP Johann Lodewijk Hillege, PRAC Rapporteur: recommendation. Menno van der Elst, “Update of sections 4.4 and 4.9 of the SmPC in order to reflect the availability of a reversal agent for apixaban following the recent approval of andexanet alfa in the EU; the Package Leaflet and Labelling are updated accordingly. The RMP version 20.1 has also been submitted, with updates due to the availability of a reversal agent and implement the revised GVP template Rev.2. As a result, the list of safety concerns has been updated and a number of safety concerns listed as missing information have been reclassified and have been removed from the RMP. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet and to update the information in the SmPC and Package Leaflet in accordance with the most recent guidance on labelling of excipients of medicinal products for human use.” Opinion adopted on 03.10.2019.
Gardasil 9 - human papillomavirus vaccine Request for supplementary information adopted [types 6, 11, 16, 18, 31, 33, 45, 52, 58] with a specific timetable. (recombinant, adsorbed) - EMEA/H/C/003852/II/0033 MSD Vaccins, Rapporteur: Kristina Dunder, PRAC Rapporteur: Jean-Michel Dogné, “Update of sections 4.2, 4.6, 4.8 and 5.1 of the SmPC in order to update the safety and immunogenicity information based on final results from study
EMA/CHMP/653553/2019 Page 23/67
V503-P004 listed as a category 3 study in the RMP (MEA007); this is an open-label phase III clinical trial to study the immunogenicity and tolerability of Gardasil 9 in adult women (27 to 45 year-olds) compared to young adult women (16 to 26 year-olds); the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update Section 4.4 of the SmPC according to the Guideline on quality aspects included in the product information for vaccines for human use (EMA/CHMP/BWP/133540/2017), and to include editorial changes in Section 5.1 of the SmPC” Request for Supplementary Information adopted on 03.10.2019.
Giotrif - afatinib - Request for supplementary information adopted EMEA/H/C/002280/II/0031 with a specific timetable. Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Update of sections 4.4 and 4.8 of the SmPC in order to add gastrointestinal (GI) perforation as an additional side effect based on summaries of clinical trial and post-marketing safety data. The Package Leaflet and the RMP are updated accordingly. The RMP version 8.0 has been submitted including also the update of the RMP due to transition to the revision 2 template as per pharmacovigilance guidance and taking in consideration the recommendation received during renewal procedure EMEA/H/C/002280/R/0026. In addition the MAH took the opportunity to correct some typographical errors in the German, Austrian and Spanish PIs, to include a linguistic review comments received from Czech Authority during linguistic review of procedure EMEA/H/C/002280/R/0026 in the SmPC and to update the list of the local representatives for Austria in the package leaflet.” Request for Supplementary Information adopted on 03.10.2019, 11.07.2019.
IBRANCE - palbociclib - Positive Opinion adopted by consensus on EMEA/H/C/003853/II/0019/G 17.10.2019. The Icelandic and Norwegian CHMP Pfizer Europe MA EEIG, Rapporteur: Filip Members were in agreement with the CHMP Josephson, PRAC Rapporteur: Hans Christian recommendation. Siersted, “Update of section 4.8 of the SmPC in order to include ILD/pneumonitis as ADRs based on a safety cumulative review together with reclassification of the risk from potential to
EMA/CHMP/653553/2019 Page 24/67
identified in the RMP (version 1.6). The Package Leaflet is updated accordingly. The MAH has also submitted the updated RMP version 1.6 in order to remove long term use from missing information in the list of safety concerns. In addition, the MAH is proposing to change the due date for submission of the final CSR of study A5481027 listed as a Category 3 study in the RMP.” Opinion adopted on 17.10.2019. Request for Supplementary Information adopted on 14.06.2019.
Imbruvica - ibrutinib - Request for supplementary information adopted EMEA/H/C/003791/II/0052, Orphan with a specific timetable. Janssen-Cilag International NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, “submission of the final report on the long term safety study PAM 3038-1, which assessed long term safety data collected from predefined cohorts of subjects treated with ibrutinib for up to 5 years or until disease progression or unacceptable toxicity at the recommended daily doses of 420 mg/day for CLL/SLL and 560 mg/day for MCL. This final report fulfils the milestone for the Post Approval Measure MEA025” Request for Supplementary Information adopted on 03.10.2019.
Insuman - insulin human - Positive Opinion adopted by consensus on EMEA/H/C/000201/II/0130 03.10.2019. The Icelandic and Norwegian CHMP Sanofi-Aventis Deutschland GmbH, Rapporteur: Members were in agreement with the CHMP Bart Van der Schueren, PRAC Rapporteur: recommendation. Jean-Michel Dogné, “Submission of the final report from a completed Phase 3 study, HUBIN-L-05335, listed as a category 3 post-authorisation efficacy / safety study in the RMP. This study covers the evaluation of Insuman Implantable 400 IU/mL in patients with Type 1 diabetes treated with the Medtronic MiniMed Implantable Pump System using Insuplant 400 IU/mL, addressing the Post-Authorisation Measure MEA040. In this application, the RMP v4.0 combines the updates related to HUBIN-L-05335 study final results and the approval of amended protocol V2 of the ongoing Post Authorization Safety Study HUBIN-C-06380 (MEA/047.4 & MEA/047.5, concerning PRAC decision: EMA/PRAC/256519/2018 dated 17-May-2018; updates are limited to Annex 3 of Part VII).”
EMA/CHMP/653553/2019 Page 25/67
Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
Jakavi - ruxolitinib - Request for supplementary information adopted EMEA/H/C/002464/II/0044 with a specific timetable. Novartis Europharm Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Annika Folin, “Update of the SmPC sections 5.1 and 4.8 with the efficacy and safety information to reflect the 5-year follow-up data from the B2301 Week 256 final clinical study report (CSR). The final analyses presented in the CSR are submitted to fulfill the Post-Authorisation Measure, therefore the Annex II.D of the Product Information is updated accordingly. The changes have been reflected in the RMP version 11 submitted with the procedure II/43.” Request for Supplementary Information adopted on 03.10.2019. Clockstop extension request For adoption.
Keytruda - pembrolizumab - Positive Opinion adopted by consensus on EMEA/H/C/003820/II/0080 17.10.2019. The Icelandic and Norwegian CHMP Merck Sharp & Dohme B.V., Rapporteur: Daniela Members were in agreement with the CHMP Melchiorri, PRAC Rapporteur: Menno van der Elst, recommendation. “To update sections 4.2, 4.4 and 4.8 of the SmPC on the safety information for immune-related endocrinopathies following a safety review for Addison’s disease/primary adrenal insufficiency. The updated RMP version 27.0 has also been agreed. The MAH also took the opportunity to include the changes in Annex II related to the new EMA QRD template version 10.1 and to update the details of the local representative of Portugal in the Package Leaflet.” Opinion adopted on 17.10.2019.
Myozyme - alglucosidase alfa - Request for supplementary information adopted EMEA/H/C/000636/II/0075 with a specific timetable. Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, “Update of sections 4.4 and 5.1 of the Summary of Product Characteristics in order to reflect change in the existing warning on immunogenicity and immunomodulation and add new clinical information on infantile onset patients (IOPD) immune tolerance induction based on data on use of immune tolerance induction in infantile onset Pompe disease patients from two exploratory Phase 4 studies
EMA/CHMP/653553/2019 Page 26/67
(AGLU03707 / MSC12817 and companion study AGLU03807/ MSC12892) and the Duke Center of Excellence Observational Study (01562). The updated RMP version 9.0 has also been submitted.” Request for Supplementary Information adopted on 03.10.2019.
Raxone - idebenone - Positive Opinion adopted by consensus on EMEA/H/C/003834/II/0016, Orphan 17.10.2019. The Icelandic and Norwegian CHMP Santhera Pharmaceuticals (Deutschland) GmbH, Members were in agreement with the CHMP Rapporteur: John Joseph Borg, PRAC Rapporteur: recommendation. Amelia Cupelli, “C.I.11 for SOB studies: Submission of the final report from study SNT-CRS-002 listed as a Specific Obligation (SOB10, former SOB2) in the Annex II of the Product Information. This is a Historical case record survey (CRS) of visual acuity data from patients with Leber’s hereditary optic neuropathy (LHON). The goal is to generate a natural history group to serve as a comparator group of idebenone-naïve patients for the open-label study SNT-IV-005 which will assess long-term efficacy and safety in patients with LHON treated with Raxone. Annex II is modified accordingly. Submission of an updated RMP version 1.8 accordingly.” Opinion adopted on 17.10.2019.
Reagila - cariprazine - Positive Opinion adopted by consensus on EMEA/H/C/002770/II/0010 03.10.2019. The Icelandic and Norwegian CHMP Gedeon Richter Plc., Rapporteur: Kristina Members were in agreement with the CHMP Dunder, PRAC Rapporteur: Ana Sofia Diniz recommendation. Martins, “Submission of in vitro metabolism study report (R188-A15) and consequential update of the Risk Management Plan (version 1.7).” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
RoActemra - tocilizumab - Positive Opinion adopted by consensus on EMEA/H/C/000955/II/0086/G 17.10.2019. The Icelandic and Norwegian CHMP Roche Registration GmbH, Rapporteur: Jan Members were in agreement with the CHMP Mueller-Berghaus, PRAC Rapporteur: Brigitte recommendation. Keller-Stanislawski, “Grouping of 3 variations: Two variations C.I.11.z supporting RMP updates: Submission of an updated RMP version 25.2 in order to: - Remove the reference to the Neutropenia Guided Questionnaire from the RMP. - Remove all references to the US Claims Database from the RMP.
EMA/CHMP/653553/2019 Page 27/67
The MAH also took the opportunity to make the following minor changes to the RMP: - Removal of study WA22479 (British Society of Rheumatology Biologics Register (BSRBR)) in response to the fulfilment of PAM MEA-045. - Removal of OTIS registry from additional pharmacovigilance activities which was erroneously retained in EU-RMP version 24.1 approved with the variation procedure EMEA/H/C/00955/II/76. - Inclusion of the ZUMA-8 (KTE-X19-108) study in routine pharmacovigilance activities in line with previous PRAC/CHMP request as part of variation procedure EMEA/H/C/000955/II/0076. - Removal of study WA29358 which was erroneously introduced into RMP v24.1 as an additional PV activity One variation C.I.4 affecting the PI: Update of sections 4.8 of the SmPC the change the frequency for anaphylaxis (fatal) and Stevens-Johnson Syndrome to “rare” and list them in the tabulated list of adverse reactions; the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes to sections 4.2, 4.8, 5.1 and 5.2 of the SmPC, the Annex IID and section 4 of the Package Leaflet.” Opinion adopted on 17.10.2019.
Signifor - pasireotide - Positive Opinion adopted by consensus on EMEA/H/C/002052/II/0041/G, Orphan 03.10.2019. The Icelandic and Norwegian CHMP Novartis Europharm Limited, Rapporteur: Members were in agreement with the CHMP Kristina Dunder, PRAC Rapporteur: Annika Folin, recommendation. “Submission of the final CSR from Study CSOM230B2219; a multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s disease or acromegaly (listed as a category 3 study in the RMP). A revised RMP version 7.1, updated in line with the revised GVP Module V, including changes to the safety concerns, was agreed during the procedure.” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 14.06.2019.
Tamiflu - oseltamivir - Request for supplementary information adopted
EMA/CHMP/653553/2019 Page 28/67
EMEA/H/C/000402/II/0142 with a specific timetable. Roche Registration GmbH, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, “Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC following completion of the paediatric studies NV25719 and NV20234 and downstream population PK and PK/PD analysis, listed in the approved Tamiflu Paediatric Investigation Plan (PIP) (EMEA-000365-PIP01-08-M10); the study NV25719 was a prospective, open-label, randomized study which investigated PK and PD of two weight adjusted oseltamivir doses for the treatment of influenza-infected immunocompromised (IC) children less than 13 years of age. The study NV20234 was a prospective, double-blind, randomized trial which investigated safety and viral resistance to oseltamivir treatment in influenza-infected IC adults, adolescents and children. The purpose of this variation is to establish a dose recommendation for the treatment of paediatric IC patients. The Package Leaflet and Labelling are updated accordingly. The updated RMP version 19 has also been submitted.” Request for Supplementary Information adopted on 17.10.2019.
Vemlidy - tenofovir alafenamide - Request for supplementary information adopted EMEA/H/C/004169/II/0020 with a specific timetable. Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Ilaria Baldelli, “Update of sections 4.8 and 5.1 of the SmPC based on safety information from interim results at Week 48 of a phase 3, randomized, double blind study (GS-US-320-4018) conducted to evaluate the efficacy and safety of switching from tenofovir disoproxil fumarate (TDF) 300 mg QD to tenofovir alafenamide (TAF) 25 mg QD in subjects with CHB who are virologically suppressed, listed as a category 3 study in the RMP; the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted.” Request for Supplementary Information adopted on 17.10.2019, 25.07.2019.
VeraSeal - human fibrinogen / human Request for supplementary information adopted thrombin - EMEA/H/C/004446/II/0006/G with a specific timetable. Instituto Grifols, S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Amelia Cupelli“B.IV.1.a.3 – Type II - To add a new CE
EMA/CHMP/653553/2019 Page 29/67
marked applicator tip The safety concern of air or gas embolism that is currently included in the Risk Management Plan (RMP) is no longer applicable, consequently the RMP has been updated accordingly (version 4.0) and is provided in Module 1.8.2. RMP version 4.0 has been restructured in order to adapt to the new format of GVP Module V. B.II.e.6.a – Type 1B B.II.e.6.a – Type 1B B.II.b.3.a – Type 1A B.II.b.3.a – Type 1A Request for Supplementary Information adopted on 17.10.2019.
Xermelo - telotristat ethyl - Positive Opinion adopted by consensus on EMEA/H/C/003937/II/0015, Orphan 03.10.2019. The Icelandic and Norwegian CHMP Ipsen Pharma, Rapporteur: Martina Weise, PRAC Members were in agreement with the CHMP Rapporteur: Adam Przybylkowski, “To update recommendation. section 5.1 of the SmPC based on final results from study LX1606.1-302.CS (TELEPATH) listed as a category 3 study in the RMP; this is a multicentre, phase III, long-term extension study to further evaluate the safety and tolerability of telotristat etiprate in patients with carcinoid syndrome (CS). The updated RMP version 4.0 has also been submitted, also updating to GVP Module V (Rev 2).” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
Yervoy - ipilimumab - Positive Opinion adopted by consensus on EMEA/H/C/002213/II/0064 03.10.2019. The Icelandic and Norwegian CHMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Members were in agreement with the CHMP Paula Boudewina van Hennik, PRAC Rapporteur: recommendation. Menno van der Elst, “Update of sections 4.4 and 4.8 of the SmPC to add stomatitis to the list of ADRs with a frequency uncommon, to further explain the components of the existing ADR musculoskeletal pain in a footnote and to update safety information based on final results from study CA184143 (A Multi-National, Prospective, Observational Study in Patients with Unresectable or Metastatic Melanoma) listed as a category 3 study in the RMP (MEA017.11); the Package Leaflet and the RMP have been updated accordingly (version 26.2). In addition, minor changes to improve clarity were introduced in section 5.1 of the SmPC and to the Annex II of the Product Information and minor changes were also made in relation to the Dutch Melanoma
EMA/CHMP/653553/2019 Page 30/67
Treatment Registry (DMTR) in the RMP, partly as recommended in conclusion to MEA 036.1.” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 14.06.2019, 14.03.2019.
B.5.4. PRAC assessed procedures
PRAC Led Positive Opinion adopted by consensus on Accofil - filgrastim - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/003956/II/0037 Members were in agreement with the CHMP Accord Healthcare S.L.U., Rapporteur: Outi recommendation. Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, PRAC-CHMP liaison: Tuomo Lapveteläinen, “Submission of an updated RMP version 4.0 in order to update the section of additional pharmacovigilance activities (removal of SCNIR and EBMT registry) in follow-up to the assessment of the `Accofil Severe Chronic Neutropenia International Registry (SCNIR)’ and ‘European Group for Blood and Marrow Transplantation (EBMT)’ Combined Analysis Report. The MAH has also taken the opportunity to implement the RMP template based on GVP module V rev.2.” Opinion adopted on 03.10.2019.
PRAC Led Positive Opinion adopted by consensus on Caprelsa - vandetanib - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/002315/II/0040 Members were in agreement with the CHMP Genzyme Europe BV, Rapporteur: Alexandre recommendation. Moreau, PRAC Rapporteur: Ghania Chamouni, PRAC-CHMP liaison: Alexandre Moreau, “Submission of an updated RMP version 13 in order to remove the Health Care Professionals survey from the list of additional Pharmacovigilance Activities and to remove several safety concerns from the list of important identified and potential risks and missing information to follow revised guidance in the GVP Module V Rev.2 as requested during variation procedure EMEA/H/C/002315/II/0028.” Opinion adopted on 03.10.2019.
PRAC Led Request for supplementary information adopted Edurant - rilpivirine - with a specific timetable. EMEA/H/C/002264/II/0037 Janssen-Cilag International NV, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “C.I.13:
EMA/CHMP/653553/2019 Page 31/67
Submission of the final report from a Drug Utilization Study (DUS), with register number EUPAS5766, in the EuroSIDA cohort listed as a category 3 study in the RMP. This is a Observational Cohort Study to assess rilpivirine (RPV) utilization according to the European SmPC. The RMP version 9.0 has also been submitted.” Request for Supplementary Information adopted on 03.10.2019.
PRAC Led Request for supplementary information adopted EXJADE - deferasirox - with a specific timetable. EMEA/H/C/000670/II/0068 Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, PRAC-CHMP liaison: Alexandre Moreau, “Submission of the final report related to the Physician Survey (NO6987) conducted for Exjade to assess the impact of educational materials on the prescribers' awareness of doses and biological monitoring recommendations and to assess the awareness and appropriate use of both formulations (Dispersible Tablets and Film-Coated tablets). The updated RMP version 17.1 is submitted as well.” Request for Supplementary Information adopted on 03.10.2019.
PRAC Led Request for supplementary information adopted Glivec - imatinib - with a specific timetable. EMEA/H/C/000406/II/0115 Novartis Europharm Limited, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Submission of an updated RMP version 12 in order to revise the lists of safety concerns in EU RMP and align with the current GVP Rev 2 based on the PRAC advice received on the latest PSUR (11-May-2015 to 10-May-2018).” Request for Supplementary Information adopted on 03.10.2019.
PRAC Led Request for supplementary information adopted Jakavi - ruxolitinib - with a specific timetable. EMEA/H/C/002464/II/0043 Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Filip Josephson, “Submission of the final report from a safety study (INC424AIC01T) of ruxolitinib in myelofibrosis
EMA/CHMP/653553/2019 Page 32/67
(MF) listed as a category 3 study in the RMP. This is a non-interventional, observational post-authorisation safety study (PASS) intended to provide real-world safety data on patients with MF who were exposed and non-exposed to ruxolitinib and thereby provide insights into disease management and the safety profile of ruxolitinib. The RMP version 11 has also been submitted. The updated RMP v11 reflects the completion of additional pharmacovigilance studies including the above-mentioned PASS (INC424AIC01T, Category 3) as well as the RESPONSE study (INC424B2301, Category 1). This RMP is incorporated in this variation and will be cross-referred in the variation forthcoming submission for the RESPONSE study within a month of this submission.” Request for Supplementary Information adopted on 03.10.2019. Clockstop extension request For adoption.
PRAC Led Positive Opinion adopted by consensus on Noxafil - posaconazole - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/000610/II/0057 Members were in agreement with the CHMP Merck Sharp & Dohme B.V., Rapporteur: recommendation. Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, “Submission of an updated RMP (version 15.1) in order to bring it in line with the guidance included in Good Pharmacovigilance Practices (GVP) Module V (Rev. 2), with the consequent applicable re-evaluation of some safety concerns. In addition to the above updates, the MAH took the opportunity to include data from the completed clinical trial in paediatric subjects PN097 (the CSR which was submitted to the Agency in February 2019: P46 029), and update the due date for submission of the final report for the ongoing post-marketing efficacy trial PN069 .” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
PRAC Led Request for supplementary information adopted Onivyde pegylated liposomal - irinotecan with a specific timetable. hydrochloride trihydrate - EMEA/H/C/004125/II/0015, Orphan Les Laboratoires Servier, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Ingrid Wang, “Submission of an updated RMP version 2.7 in
EMA/CHMP/653553/2019 Page 33/67
order to update the RMP further to the last PSUSA procedures (PSUSA/00010534/201804 and (PSUSA/00010534/201810) and in accordance with GVP Module V Rev.2.” Request for Supplementary Information adopted on 03.10.2019.
PRAC Led Positive Opinion adopted by consensus on ProQuad - measles, mumps, rubella and 03.10.2019. The Icelandic and Norwegian CHMP varicella vaccine (live) - Members were in agreement with the CHMP EMEA/H/C/000622/II/0134 recommendation. MSD Vaccins, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Submission of an updated RMP (version 6.1) in order to adhere to Version 2 of the RMP template. As a consequence, the following changes are carried out: - Removal of the important identified risks febrile seizure, fever, measles-like rash, and thrombocytopenia and the addition of disseminated disease caused by Oka/Merck vaccine virus strain. - The important potential risks varicella-like or herpes zoster-like rashes, potential central nervous system events, potential transmission of varicella vaccine virus strain, exposure of immunocompromised individuals, hypersensitivity including anaphylaxis and injection-site reactions are also removed. - Additionally, secondary transmission of Oka/Merck vaccine virus strain in susceptible high-risk individuals leading to severe clinical consequences is included. - The important missing information ‘categories exposure during pregnancy’ and ‘safety and immunogenicity in patients less than 9 months’ of age is also removed.” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 16.05.2019.
PRAC Led Positive Opinion adopted by consensus on Rebetol - ribavirin - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/000246/II/0086 Members were in agreement with the CHMP Merck Sharp & Dohme B.V., PRAC Rapporteur: recommendation. Adrien Inoubli, PRAC-CHMP liaison: Jean-Michel Race, “Submission of an updated RMP version 6.0 in order to revise safety concerns for ribavirin based on GVP module V (rev. 2) guidance. In addition, the MAH took the opportunity to revise the safety concerns of ribavirin in light of the
EMA/CHMP/653553/2019 Page 34/67
current era of IFN free regimen, as requested in a previous PSUSA procedure (EMEA/H/C/PSUSA/00010007/201707).” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
PRAC Led Positive Opinion adopted by consensus on Sutent - sunitinib - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/000687/II/0073 Members were in agreement with the CHMP Pfizer Europe MA EEIG, Rapporteur: Daniela recommendation. Melchiorri, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Daniela Melchiorri, “Submission of an updated RMP version 17.2 in order to review the list of safety concerns to make it more risk proportionate based on available safety data. The updates are in line with the new GVP Module V (Rev 2) guideline and new RMP template.” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 16.05.2019, 17.01.2019.
PRAC Led Positive Opinion adopted by consensus on Tysabri - natalizumab - 03.10.2019. The Icelandic and Norwegian CHMP EMEA/H/C/000603/II/0114 Members were in agreement with the CHMP Biogen Netherlands B.V., Rapporteur: Jan recommendation. Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Update of the RMP (version 25.0) with data on extended interval dosing, including an update to part II, Part VI and Annex 6. In order to align with the changes in the RMP, the MAH also submitted PI with changes in the annex I and II. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and add some QRD V10.1 requirement such as a statement on batch traceability in annex I and III (PL).” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 11.07.2019.
PRAC Led Positive Opinion adopted by consensus on WS1586 03.10.2019. The Icelandic and Norwegian CHMP Anoro Ellipta-EMEA/H/C/002751/ Members were in agreement with the CHMP WS1586/0028 recommendation. Laventair Ellipta-EMEA/H/C/003754/ WS1586/0031 GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Peter Kiely, Lead PRAC Rapporteur:
EMA/CHMP/653553/2019 Page 35/67
Ilaria Baldelli, PRAC-CHMP liaison: Daniela Melchiorri, “Submission of an updated RMP version 8.0 following the renewal procedures (EMEA/H/C/4002751/R/0022 and EMEA/H/C/003754/R/0025) commitments to remove the important identified risks of ‘hypersensitivity’ and ‘paradoxical bronchospasm’ from the list of safety concerns and to update all relevant sections of the RMP in line with revision 2 of GVP module V on ‘Risk management systems’ and revision 2 of the guidance on the format of the RMP in the EU (template). In addition, the important potential risks of ‘narrow angle glaucoma’ and ‘bladder outflow obstruction and urinary retention’ are removed; as well as the missing information on ‘safety in pregnancy and lactation’, ‘safety in long-term use’ and ‘safety in severe hepatic impairment’.” Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 16.05.2019.
PRAC Led Positive Opinion adopted by consensus on WS1614 03.10.2019. The Icelandic and Norwegian CHMP Enbrel-EMEA/H/C/000262/WS1614/0227 Members were in agreement with the CHMP LIFMIOR-EMEA/H/C/004167/WS1614/ recommendation. 0021 Pfizer Europe MA EEIG, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Submission of the final report for the PURPOSE study, a category 3 study in the RMP. PURPOSE was a non-interventional, multi-centre, prospective, observational, cohort study to evaluate the long-term safety and effectiveness of etanercept prescribed by dermatologists to paediatric patients for the treatment of plaque psoriasis.” Opinion adopted on 03.10.2019.
PRAC Led Positive Opinion adopted by consensus on WS1651 03.10.2019. The Icelandic and Norwegian CHMP Idacio-EMEA/H/C/004475/WS1651/0003 Members were in agreement with the CHMP Kromeya-EMEA/H/C/005158/WS1651/ recommendation. 0003 Fresenius Kabi Deutschland GmbH, Lead PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “To update the risk management plans (RMP) for Idacio and Kromeya in order to align it with the parent product Humira one.
EMA/CHMP/653553/2019 Page 36/67
The Risk Minimization Measures in Annex II.D of the PI are also updated. Minor linguistic changes/corrections to the Product Information in German, French, Hungarian (Idacio only) and Slovenian have been included.” Opinion adopted on 03.10.2019.
PRAC Led Positive Opinion adopted by consensus on WS1663/G 03.10.2019. The Icelandic and Norwegian CHMP Exviera-EMEA/H/C/003837/WS1663/ Members were in agreement with the CHMP 0046/G recommendation. Viekirax-EMEA/H/C/003839/WS1663/ 0055/G AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “C.I.13 To submit the final report from study P15-421, listed as a category 3 study in the RMP. This was a prospective, observational cohort study utilizing the Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET) data to evaluate the clinical impact and real world frequency of Grade 3+ ALT elevations in patients being treated for Hepatitis C with paritaprevir with ritonavir (paritaprevir/r), ombitasvir and dasabuvir (3-DAA regimen) or paritaprevir/r and ombitasvir (2-DAA regimen) with or without ribavirin for Hepatitis C Infection (HCV). C.I.11.Z (Type IB): To change the final due date for the prospective safety study report in order to evaluate the recurrence of hepatocellular carcinoma associated with Viekirax and Exviera from Q2 2021 to Q2 2023. Annex II of the Product Information is updated accordingly. An updated RMP version 5.0 has also been submitted in order to convert the RMP to the new format and to remove some safety concerns and activities from the PhV Plan that have already been finalised.” Opinion adopted on 03.10.2019.
PRAC Led Positive Opinion adopted by consensus on WS1671 03.10.2019. The Icelandic and Norwegian CHMP Afinitor-EMEA/H/C/001038/WS1671/ Members were in agreement with the CHMP 0063 recommendation. Votubia-EMEA/H/C/002311/WS1671/ 0059 Novartis Europharm Limited, Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, “To
EMA/CHMP/653553/2019 Page 37/67
update the RMP for Afinitor and Votubia to version 14.0 to change the safety concerns, to reflect the completion of pharmacovigilance studies [CRAD001Y2201 (Afinitor II/0058), CRAD001M2304 (Votubia II/0051), CRAD001J2301 (Afinitor II/0051/G), CRAD00W2301 (Afinitor II/0051/G)] and to implement the latest GVP module V rev.2 template; the change has been agreed by the PRAC in the outcome of a PSUR assessment (EMEA/H/C/PSUSA/00010268/201703).” Opinion adopted on 03.10.2019.
PRAC Led Request for supplementary information adopted WS1680 with a specific timetable. Actos-EMEA/H/C/000285/WS1680/0082 Competact-EMEA/H/C/000655/WS1680/ 0074 Glubrava-EMEA/H/C/000893/WS1680/ 0060 Glustin-EMEA/H/C/000286/WS1680/0081 Tandemact-EMEA/H/C/000680/WS1680/ 0060 Takeda Pharma A/S, Lead Rapporteur: Peter Kiely, Lead PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, “Submission of an updated RMP (version 27) in order to update and consolidate within a single RMP the RMPs for Pioglitazone, Pioglitazone/Metformin fixed dose combination (FDC) and Pioglitazone/Glimepiride FDC. The list of safety concerns has also been reviewed and consolidated RMP version updated with information agreed/approved as part of the PSUR procedure (EMEA/H/C/PSUSA/00002417/201807) with regards to discontinuation of pioglitazone aRMMs.” Request for Supplementary Information adopted on 03.10.2019.
B.5.5. CHMP-CAT assessed procedures
YESCARTA - axicabtagene ciloleucel - Positive Opinion adopted by consensus on EMEA/H/C/004480/II/0011, Orphan, 17.10.2019. The Icelandic and Norwegian CHMP ATMP Members were in agreement with the CHMP Kite Pharma EU B.V., Rapporteur: Jan recommendation. Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Opinion adopted on 17.10.2019, 11.10.2019. Request for Supplementary Information adopted
EMA/CHMP/653553/2019 Page 38/67
on 13.09.2019.
Zynteglo - autologous cd34+ cell enriched See 9.1 population that contains hematopoietic Positive Opinion adopted by consensus on stem cells transduced with lentiglobin 17.10.2019. The Icelandic and Norwegian CHMP bb305 lentiviral vector encoding the Members were in agreement with the CHMP beta-a-t87q-globin gene - recommendation. EMEA/H/C/003691/II/0001/G, Orphan, ATMP bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik Opinion adopted on 17.10.2019, 11.10.2019. Request for Supplementary Information adopted on 13.09.2019.
B.5.6. CHMP-PRAC-CAT assessed procedures
Strimvelis - autologous CD34+ enriched cell Positive Opinion adopted by consensus on fraction that contains CD34+ cells 17.10.2019. The Icelandic and Norwegian CHMP transduced with retroviral vector that Members were in agreement with the CHMP encodes for the human ADA cDNA sequence recommendation. - EMEA/H/C/003854/II/0022, Orphan, ATMP Orchard Therapeutics (Netherlands) BV, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst, “Submission of an updated RMP version 2.0 in order to introduce changes to the design of the post-authorisation study STRIM-002, from a prospective to a retrospective study. Following additional minor changes to the RMP are also included: Update of the RMP in line with EMA Rev.2.0.1 template; update of the RMP to make the necessary amendments to the name of the MAH following the MAH transfer; update of the data in the RMP in line with the updated data lock point; update of timelines for the STRIM-001 study.” Opinion adopted on 17.10.2019, 11.10.2019.
B.5.7. PRAC assessed ATMP procedures
B.5.8. Unclassified procedures and worksharing procedures of type I variations
WS1645 Positive Opinion adopted by consensus on Exelon-EMEA/H/C/000169/WS1645/0123 03.10.2019. The Icelandic and Norwegian CHMP Prometax-EMEA/H/C/000255/WS1645/ Members were in agreement with the CHMP 0124 recommendation.
EMA/CHMP/653553/2019 Page 39/67
Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau Opinion adopted on 03.10.2019. Request for Supplementary Information adopted on 25.07.2019.
WS1676/G Positive Opinion adopted by consensus on Exelon-EMEA/H/C/000169/WS1676/ 26.09.2019. The Icelandic and Norwegian CHMP 0124/G Members were in agreement with the CHMP Prometax-EMEA/H/C/000255/WS1676/ recommendation. 0125/G Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau Opinion adopted on 26.09.2019.
WS1681 Positive Opinion adopted by consensus on Esperoct-EMEA/H/C/004883/WS1681/ 17.10.2019. The Icelandic and Norwegian CHMP 0001 Members were in agreement with the CHMP NovoEight-EMEA/H/C/002719/WS1681/ recommendation. 0032 Novo Nordisk A/S, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 17.10.2019.
WS1687 Fiasp-EMEA/H/C/004046/WS1687/0017 NovoMix-EMEA/H/C/000308/WS1687/ 0100 NovoRapid-EMEA/H/C/000258/WS1687/ 0130 Ryzodeg-EMEA/H/C/002499/WS1687/ 0037 Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder
WS1697 Positive Opinion adopted by consensus on Ebymect-EMEA/H/C/004162/WS1697/ 17.10.2019. The Icelandic and Norwegian CHMP 0040 Members were in agreement with the CHMP Xigduo-EMEA/H/C/002672/WS1697/0051 recommendation. AstraZeneca AB, Lead Rapporteur: Kristina Dunder Opinion adopted on 17.10.2019.
B.5.9. Information on withdrawn type II variation / WS procedure
OPDIVO - nivolumab - The MAH withdrew the procedure on 11.10.2019. EMEA/H/C/003985/II/0065 Bristol-Myers Squibb Pharma EEIG, Co-Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update posology and clinical related
EMA/CHMP/653553/2019 Page 40/67
information based on interim results from Phase 3b/4 Study CA209384 (A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks.) and further supported by pharmacometric analyses in subjects with 2L+ NSCLC.” Request for Supplementary Information adopted on 27.06.2019. Withdrawal request submitted on 11.10.2019.
Zytiga - abiraterone acetate - The MAH withdrew the procedure on 23.09.2019. EMEA/H/C/002321/II/0054/G Janssen-Cilag International NV, Rapporteur: Jorge Camarero Jiménez Request for Supplementary Information adopted on 26.04.2019, 14.02.2019. Withdrawal request submitted on 23.09.2019.
Zytiga - abiraterone acetate - The MAH withdrew the procedure on 17.10.2019. EMEA/H/C/002321/II/0059 Janssen-Cilag International NV, Rapporteur: Jorge Camarero Jiménez, “To update sections 4.4 and 4.8 of the SmPC with safety information on QT prolongation and Torsades de Pointes following a cumulative review of QT Prolongation/Torsades de pointes occurrence.” Request for Supplementary Information adopted on 10.10.2019. Withdrawal request submitted on 17.10.2019.
OPDIVO - nivolumab - The MAH withdrew the procedure on 11.10.2019 EMEA/H/C/003985/II/0065 Bristol-Myers Squibb Pharma EEIG, Co-Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update posology and clinical related information based on interim results from Phase 3b/4 Study CA209384 (A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks.) and further supported by pharmacometric analyses in subjects with 2L+ NSCLC.” Request for Supplementary Information adopted on 27.06.2019.
EMA/CHMP/653553/2019 Page 41/67
B.5.10. Information on type II variation / WS procedure with revised timetable
WS1524 The CHMP agreed to the request for an extension HyQvia-EMEA/H/C/002491/WS1524/0048 to the clock stop to respond to the Request for Kiovig-EMEA/H/C/000628/WS1524/0090 Supplementary Information adopted in Baxter AG, Lead Rapporteur: Jan September 2019. Mueller-Berghaus
Request for Supplementary Information adopted on 19.09.2019, 14.03.2019.
Yondelis - trabectedin - The CHMP agreed to the request for an extension EMEA/H/C/000773/II/0058, Orphan to the clock stop to respond to the RSI adopted in Pharma Mar, S.A., Rapporteur: Sinan B. Sarac, September 2019. PRAC Rapporteur: Hans Christian Siersted, “Update of section 4.4 of the SmPC in order to add a warning based on results from study Cardiac Safety Report [Protocols ET743-SAR-3007, ET743-OVA-301, ET743-OVC-3006; Phase 3. JNJ-17027907; R270741 (trabectedin)] following the PSUSA procedure EMEA/H/C/PSUSA/00003001/201809; the Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 19.09.2019.
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION
B.6.1. Start of procedure for New Applications: timetables for information abiraterone acetate - EMEA/H/C/005408 treatment of metastatic prostate cancer bevacizumab - EMEA/H/C/005181 Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First line treatment of patients with advanced and/or metastatic renal cell cancer. lenalidomide - EMEA/H/C/005306 treatment of multiple myeloma pegfilgrastim - EMEA/H/C/005085 treatment of neutropenia somapacitan - EMEA/H/C/005030, Orphan Novo Nordisk A/S, indicated for the replacement of endogenous GH with growth hormone
EMA/CHMP/653553/2019 Page 42/67
deficiency (AGHD)
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information
IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/X/0035, Orphan CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, “Extension application to add a new strength of 3500 IU (700 IU/ml) for albutrepenonacog alfa powder and solvent for solution for injection. The RMP version 3.1 was updated in accordance. In addition, the applicant took the opportunity to update sections with editorial changes and align the dossier.”
Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/X/0010 Accord Healthcare S.L.U., Generic, Generic of Alimta, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ghania Chamouni, “Extension application to introduce a new pharmaceutical form associated with new strength (25 mg/ml solution for infusion)”
Velphoro - iron - EMEA/H/C/002705/X/0020/G Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Kimmo Jaakkola, “Extension application to add a new pharmaceutical form with a new strength - powder for oral suspension 125 mg, and extension of indication to add indication to use Velphoro for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate <30 mL/min/1.73 m2) or with CKD on dialysis, based on the results from an open-label, randomised, active-controlled, parallel group, multicentre, phase 3 study investigating the safety and efficacy of Velphoro and calcium acetate in paediatric and adolescent CKD patients with hyperphosphataemia (Study PA-CL-PED-01). As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. In addition, the MAH took the opportunity to update the list of
EMA/CHMP/653553/2019 Page 43/67
local representatives in the Package Leaflet. The RMP version 7.0 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1.” Request for 1 year of data exclusivity for a new indication (Article 10(5) of Directive 2001/83/EC)
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information arsenic trioxide - EMEA/H/C/005235 treatment of relapsed acute promyelocytic leukaemia (APL) List of Questions adopted on 25.07.2019. azacitidine - EMEA/H/C/004984 treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) List of Questions adopted on 25.07.2019. doxorubicin - EMEA/H/C/005194 treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma List of Questions adopted on 19.09.2019.
Entyvio - vedolizumab - EMEA/H/C/002782/X/0040 Takeda Pharma A/S, Rapporteur: Daniela Melchiorri, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Adam Przybylkowski, “Extension application to introduce a new pharmaceutical form (solution for injection), associated with a new strength (108 mg) and a new route of administration (subcutaneous use).” List of Questions adopted on 25.07.2019. influenza vaccine (surface antigen, inactivated) - EMEA/H/C/004993, Article 28 Active immunisation against influenza in the elderly (65 years of age and older) and in children 6 months to less than 6 years of age List of Questions adopted on 25.07.2019.
IBRANCE - palbociclib - EMEA/H/C/003853/X/0018 Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, “Extension application to introduce a new pharmaceutical form (film-coated tablets)
EMA/CHMP/653553/2019 Page 44/67
associated with new strengths.” List of Questions adopted on 25.07.2019.
Kymriah - tisagenlecleucel - EMEA/H/C/004090/X/0010, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, Co-Rapporteur: Dariusz Sladowski, CHMP Coordinators: Ingrid Wang, Ewa Balkowiec Iskra List of Questions adopted on 13.09.2019.
Pemetrexed Fresenius Kabi - pemetrexed - EMEA/H/C/003895/X/0009 Fresenius Kabi Deutschland GmbH, Generic, Generic of Alimta, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Ghania Chamouni, “Extension application to introduce a new pharmaceutical form (concentrate for solution for infusion) associated with new strength 25 mg/ml.” List of Outstanding Issues adopted on 19.09.2019. List of Questions adopted on 31.01.2019. rituximab - EMEA/H/C/004696 treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL) and Rheumatoid arthritis List of Questions adopted on 13.12.2018. semaglutide - EMEA/H/C/004953 treatment of type 2 diabetes mellitus List of Questions adopted on 19.09.2019. isatuximab - EMEA/H/C/004977, Orphan sanofi-aventis groupe, For the treatment of patients with multiple myeloma (MM) List of Questions adopted on 19.09.2019. treprostinil sodium - EMEA/H/C/005207, Orphan SciPharm Sarl, treatment of thromboembolic pulmonary hypertension (CTEPH) List of Questions adopted on 27.06.2019. pexidartinib - EMEA/H/C/004832, Orphan Daiichi Sankyo Europe GmbH, treatment of adult patients with symptomatic tenosynovial giant cell tumour (TGCT), also referred to as giant cell tumour of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS) List of Questions adopted on 25.07.2019. lifitegrast - EMEA/H/C/004653 treatment of moderate to severe dry eye disease
EMA/CHMP/653553/2019 Page 45/67
in adults for whom prior artificial tears has not been sufficient List of Questions adopted on 26.04.2019. ozanimod - EMEA/H/C/004835 Treatment of multiple sclerosis List of Questions adopted on 25.07.2019.
B.6.4. Annual Re-assessments: timetables for adoption
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed
Bosulif - bosutinib - EMEA/H/C/002373/R/0039 Pfizer Europe MA EEIG, Rapporteur: Janet Koenig, Co-Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Martin Huber
Natpar - parathyroid hormone - EMEA/H/C/003861/R/0022, Orphan Shire Pharmaceuticals Ireland Limited, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Rhea Fitzgerald
B.6.6. VARIATIONS – START OF THE PROCEDURE
Timetables for adoption provided that the validation has been completed.
B.6.7. Type II Variations scope of the Variations: Extension of indication
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects
Apidra - insulin glulisine - EMEA/H/C/000557/II/0082/G Sanofi-Aventis Deutschland GmbH, Rapporteur: Mark Ainsworth
BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0161/G Pfizer Europe MA EEIG, Rapporteur: Jan Mueller-Berghaus
Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0085/G UCB Pharma S.A., Rapporteur: Kristina Dunder
Coagadex - human coagulation factor X - EMEA/H/C/003855/II/0023, Orphan BPL Bioproducts Laboratory GmbH, Rapporteur: Andrea Laslop
EMA/CHMP/653553/2019 Page 46/67
Request for Supplementary Information adopted on 24.10.2019.
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0002, Orphan Novo Nordisk A/S, Rapporteur: Andrea Laslop
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0008 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz
Fulphila - pegfilgrastim - EMEA/H/C/004915/II/0005/G Mylan S.A.S, Rapporteur: Martina Weise
Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0037, Orphan Roche Registration GmbH, Rapporteur: Sinan B. Sarac
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0111/G CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus
Ilumetri - tildrakizumab - EMEA/H/C/004514/II/0010/G Almirall S.A, Rapporteur: Jan Mueller-Berghaus
Inflectra - infliximab - EMEA/H/C/002778/II/0081/G Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola
Kyprolis - carfilzomib - EMEA/H/C/003790/II/0040, Orphan Amgen Europe B.V., Rapporteur: Jorge Camarero Jiménez
NovoEight - turoctocog alfa - EMEA/H/C/002719/II/0033/G Novo Nordisk A/S, Rapporteur: Jan Mueller-Berghaus
OPDIVO - nivolumab - EMEA/H/C/003985/II/0076/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jorge Camarero Jiménez
OPDIVO - nivolumab - EMEA/H/C/003985/II/0078 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jorge Camarero Jiménez
Orkambi - lumacaftor / ivacaftor -
EMA/CHMP/653553/2019 Page 47/67
EMEA/H/C/003954/II/0053/G Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Daniela Melchiorri
Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/II/0025 Eurocept International B.V., Rapporteur: Jayne Crowe
Posaconazole AHCL - posaconazole - EMEA/H/C/005028/II/0001 Accord Healthcare S.L.U., Generic, Generic of Noxafil, Rapporteur: Kolbeinn Gudmundsson
Remsima - infliximab - EMEA/H/C/002576/II/0075/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola
Somavert - pegvisomant - EMEA/H/C/000409/II/0091 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race
Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0020 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege
Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0020/G Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege
WS1726 Nuwiq-EMEA/H/C/002813/WS1726/0033 Vihuma-EMEA/H/C/004459/WS1726/ 0015 Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects
Aptivus - tipranavir - EMEA/H/C/000631/II/0083/G Boehringer Ingelheim International GmbH, Rapporteur: Jean-Michel Race, “C.1.4 (type II) - Update section 5.3 of the SmPC in order to update the preclinical safety information based on the outcome of ICH M7 assessment.
EMA/CHMP/653553/2019 Page 48/67
B.I.b.1.h (type IB) B.II.b.2.a (type IA) B.II.d.1.g (type IB) B.II.f.1.a.1 (type IB) B.II.f.1.d (type IB) B.II.f.1.e (type IB) The Package Leaflet and Labelling are updated accordingly.”
Bydureon - exenatide - EMEA/H/C/002020/II/0066 AstraZeneca AB, Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC to include information about the new ADR drug-induced thrombocytopenia (DITP) based on spontaneous reports post-marketing. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in line with the latest QRD template.”
BYETTA - exenatide - EMEA/H/C/000698/II/0071 AstraZeneca AB, Rapporteur: Kristina Dunder, “Update of section 4.8 of the SmPC to include information about the new ADR drug-induced thrombocytopenia (DITP) based on spontaneous reports post-marketing. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in line with the latest QRD template.”
Harvoni - ledipasvir / sofosbuvir - EMEA/H/C/003850/II/0082 Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, “Update of section 5.3 of the SmPC in order to add new information on ledipasvir carcinogenicity based on final results from study TX-256-2016; this was a 104-week oral gavage carcinogenicity study in rats.”
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0004 Bayer AG, Rapporteur: Sinan B. Sarac, “Submission of the final Clinical Study Report PH-40657 for the pharmacokinetic study (study 19096) comparing pharmacokinetic parameters of Jivi vs. Elocta.”
Lorviqua - lorlatinib - EMEA/H/C/004646/II/0002 Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, “Update of section 4.5 of the SmPC in order to further reflect the induction potential of
EMA/CHMP/653553/2019 Page 49/67
lorlatinib on CYP2C9, P-gp, CYP2B6 and UGT1A1 substrates based on the results from the drug-drug interaction sub-study of B7461001. Furthermore, the MAH corrected information regarding ADRs in sections 4.4 and 4.8 of the SmPC and clarification regarding linearity/non-linearity of lorlatinib PK in section 5.2 of the SmPC. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.1.”
MabThera - rituximab - EMEA/H/C/000165/II/0169 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update of the SmPC sections 4.8, 5.1 and 5.2. with the results of the Post-authorisation efficacy study (PAES) randomised phase 3 study (PEMPHIX WA29330) which further investigated the efficacy of Mabthera in the subgroup of patients with established PV as well as characterised its long term efficacy and safety on disease progression. Annex II and PL are updated accordingly.”
Mepsevii - vestronidase alfa - EMEA/H/C/004438/II/0009, Orphan Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.8. 5.1 and 5.2 of the SmPC following final results from paediatric study UX003-CL203, an open –label study of vestrodinase alfa enzyme replacement therapy in MPS 7 patients less than 5 years old.”
Nerlynx - neratinib - EMEA/H/C/004030/II/0007 Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, “Update of section 5.1 of the SmPC to update the results of the multicentre, randomised, double-blind, placebo-controlled, pivotal phase III study, ExteNET (3004) in women with early-stage HER2-positive breast cancer who had completed adjuvant treatment with trastuzumab, based on a re-analysis conducted with corrected stratification factors. Furthermore the MAH took the opportunity to make some corrections in section 4.4 of the SmPC.”
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0003 Portola Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, “Submission of the final report
EMA/CHMP/653553/2019 Page 50/67
from Population PK and PK/PD Modelling Report (POR-PKPD-ADEX-321) listed as a category 2 study in the RMP/Specific Obligation 004 in Annex II.”
Portrazza - necitumumab - EMEA/H/C/003886/II/0017 Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene, “Submission of the exploratory biomarker analysis from 4 clinical studies (I4X-MC-JFCU, I4X-MC-JFCQ, I4X-MC-JFCP, I6A-MC-CBBE) listed as a category 3 measure in the RMP. The RMP version 8.1 has also been submitted.”
Praluent - alirocumab - EMEA/H/C/003882/II/0051 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.4 of the SmPC to add a new warning on angioedema and update of section 4.8 of the SmPC to add ‘angioedema’ as a new adverse drugs reaction, based on safety review of post-marketing cases and cases from study EFC11570 (OUTCOMES study); the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make some formatting changes throughout the product information.”
PREVYMIS - letermovir - EMEA/H/C/004536/II/0014, Orphan Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, “Update of section 4.5 of the SmPC in order to update the safety information with regard to the drug interaction information following the results from study MK-8228-039, a clinical pharmacology trial entitled “A Study to Assess the Effect of P-gp/BCRP Inhibition, following Multiple Oral Doses of Itraconazole, on the Steady-State Pharmacokinetics of MK-8228 in Healthy Adult Subjects” listed as a category 3 study in the RMP. The RMP version has not been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to submit the protein binding report as part of the rifampin study MK-8228-038 as it was requested within the previous type II variation (EMEA/H/C/004536/II/0011) .”
PREVYMIS - letermovir - EMEA/H/C/004536/II/0016/G, Orphan
EMA/CHMP/653553/2019 Page 51/67
Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, “C.I.4 (type II) – Update of sections 4.4 and 6.6 of the SmPC to include the recommendation to use an in-line filter at the point of administration for finished product Prevymis 240 mg and 480 mg concentrate for solution for infusion (EU/1/17/1245/003-004). The package leaflet and labelling are updated accordingly. B.II.d.1.z (type IB) C.1.11.z (type IB) - Change in the due date of the Annex II condition for the medicinal product Prevymis 240 mg and 480 mg concentrate for solution for infusion (EU/1/17/1245/003-004) from 31 May 2020 to 31 May 2021.”
Qutenza - capsaicin - EMEA/H/C/000909/II/0048 Grunenthal GmbH, Rapporteur: Bruno Sepodes, “Update of sections 4.2 and 5.1 of the SmPC in order to amend the posology based on PACE and STRIDE studies. The Package Leaflet is updated accordingly.”
Revatio - sildenafil - EMEA/H/C/000638/II/0086 Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2 and 5.1 of the SmPC based on the final results from study A1481316; this is a multi-centre, randomised, placebo-controlled, double-blind, two-armed, parallel group study to evaluate efficacy and safety of iv sildenafil in the treatment of neonates with persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory failure and at risk for PPHN, with a long-term follow-up investigation of developmental progress 12 and 24 months after completion of study treatment. In addition some minor editorial updates to the Product Information are being proposed.”
Soliris - eculizumab - EMEA/H/C/000791/II/0107, Orphan Alexion Europe SAS, Rapporteur: Jorge Camarero Jiménez, “Submission of the final report from study ECU-MG-302, a phase III, open-label, extension trial of ECU-MG-301 to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (EudraCT 2013-002191-41).”
Strensiq - asfotase alfa - EMEA/H/C/003794/II/0043/G, Orphan
EMA/CHMP/653553/2019 Page 52/67
Alexion Europe SAS, Rapporteur: Daniela Melchiorri, “Type IB B.II.f.1.z. – To extend the time out of refrigeration (TOR) of the Strensiq vials from 1 to 3 hours. Section 6.3 of the SmPC and the Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to align the annexes with the latest QRD template v. 10.1 and to update the Package Leaflet section “How to inject Strensiq” with the clarification of the steps for injection, in order to align the instructions for injection with the EU RMP educational materials.”
Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0021/G Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, “C.I.13: Submission of the final report from study GS-US-311-1717, listed as a category 3 study in the RMP. This is a randomized, double-blind, active-controlled study to evaluate the safety and efficacy of switching to emtricitabine/tenofovir alafenamide (F/TAF) versus continuing abacavir/lamivudine (ABC/3TC) in HIV-1 infected subjects who were virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen containing ABC/3TC after 96 weeks. The RMP version 6.1 has also been submitted. C.I.11.z: Submission of an updated RMP version 6.1 in order to postpone the due date of the final report from study GS-US-292-0109 .”
Tecentriq - atezolizumab - EMEA/H/C/004143/II/0030 Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC to reflect the outcome of anti-drug antibody (ADA) analyses conducted across studies POPLAR, OAK, IMpower 150, IMpower 130, IMPower 131, IMpower 132, IMvigor 211, IMmotion 151, IMpower 133 and IMpassion 130, further to the CHMP recommendation.”
Verzenios - abemaciclib - EMEA/H/C/004302/II/0008 Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC to include the results of the interim OS analysis from study MONARCH 2, a randomised, double-blind, placebo-controlled, phase 3 study of fulvestrant
EMA/CHMP/653553/2019 Page 53/67
with or without abemaciclib, for women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer.”
Xagrid - anagrelide - EMEA/H/C/000480/II/0086 Shire Pharmaceuticals Ireland Limited, Rapporteur: Alexandre Moreau, “Update of section 4.8 of the SmPC to include the adverse drug reaction Prinzmetal angina with a frequency not known. The PIL is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes throughout the product information.”
Zessly - infliximab - EMEA/H/C/004647/II/0011 Sandoz GmbH, Rapporteur: Bjorg Bolstad, “Submission of the final CSR for the efficacy and safety study GP11-301; the report includes results from treatment period 3, where all subjects continued to receive open-label Zessly treatment for an additional 24 weeks (Week 54 until Week 78).”
WS1689 Leganto-EMEA/H/C/002380/WS1689/ 0031 Neupro-EMEA/H/C/000626/WS1689/0085 UCB Pharma S.A., Lead Rapporteur: Bruno Sepodes, “Update of section 4.8 of the SmPC in order to include “Rhabdomyolysis” as undesirable effect with frequency “not known” and widen the scope of an existing undesirable effect “increased CPK” based on new pharmacovigilance data. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant took the opportunity to correct some minor editorial discrepancies found within the package leaflets of Germany, Italy, France and Sweden.”
WS1702 Fertavid-EMEA/H/C/001042/WS1702/ 0046 Puregon-EMEA/H/C/000086/WS1702/ 0104 Merck Sharp & Dohme B.V., Lead Rapporteur: Peter Kiely, “To update of section 4.4 of the SmPC in order to revise the safety information regarding Ovarian Hyperstimulation Syndrome (OHSS) to replace clinical advice describing specific interventions with the recommendation to follow current clinical practice for reducing the
EMA/CHMP/653553/2019 Page 54/67
risk of OHSS during Assisted Reproductive Technology (ART), based on post-marketing data and literature review. The package leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflet and made some editorial changes in the Product Information.”
WS1714 OPDIVO-EMEA/H/C/003985/WS1714/ 0077 Yervoy-EMEA/H/C/002213/WS1714/0073 Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.2 and 4.4 of the SmPC in order to update the safety information on myocarditis management for nivolumab monotherapy or for nivolumab in combination with ipilimumab therapy.”
WS1722 OFEV-EMEA/H/C/003821/WS1722/0029 Vargatef-EMEA/H/C/002569/WS1722/ 0028 Boehringer Ingelheim International GmbH, Lead Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC in order to add alopecia with a frequency uncommon for Ofev and very common for Vargatef; and headache with a frequency of common for both Ofev and Vargatef as new adverse drug reactions based on an overall assessment of the safety data for the nintedanib products. The Package Leaflet is updated accordingly. In addition, the Worksharing applicant (WSA) took the opportunity to include the latest renewal date for Vargatef.”
B.6.10. CHMP-PRAC assessed procedures
AJOVY - fremanezumab - EMEA/H/C/004833/II/0003 TEVA GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kirsti Villikka, “Update of section 4.8 of the SmPC in order to update the safety information based on final results from study TV48125-CNS-30051 listed as a category 3 study in the RMP; A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating
EMA/CHMP/653553/2019 Page 55/67
the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted.”
Benlysta - belimumab - EMEA/H/C/002015/II/0073 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, “Submission of the final report from study BEL116027 listed as a category 3 study in the RMP. This is a multi-centre, open-label, non-randomized, efficacy and safety study to evaluate treatment holidays and rebound phenomenon after treatment with belimumab 10 mg/kg in subjects with low SLE disease activity. The RMP version 34 has also been submitted.”
Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/II/0044 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, “Submission of the final report from Study GS-US-311-1717 “A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens Containing ABC/3TC” , listed as additional pharmacovigilance activity in the Descovy EU Risk Management Plan (RMP). This submission provides efficacy, clinical virology and safety data for virologically suppressed HIV-infected, who switch to regimens containing F/TAF from regimens containing abacavir (ABC)/lamivudine (3TC). No amendments are proposed to the Summary of Products Characteristics, product labelling and Patient Information Leaflet for the product. The RMP version 4.1 has been submitted.”
Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0030 Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, “Change in the legal status of Fortacin from ‘medicinal product subject to medical prescription’ to ‘medicinal product not subject to medical prescription’ in view of the safety profile of Fortacin, the post-marketing experience already available with other medicinal products containing amide local anaesthetics and
EMA/CHMP/653553/2019 Page 56/67
in view of making the product more accessible to the target population. Furthermore, the PI is being brought in line with the latest QRD template (version 10.1). The RMP version 3.1 has also been submitted.”
Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0036, Orphan Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, “Update of sections 4.8 and 5.1 of the SmPC based on data from the final CSR of the pivotal study GA04753g/GO01297/GADOLIN to fulfill a Category 3 [MEA] PAM. The PL and RMP are updated accordingly.”
Incresync - alogliptin / pioglitazone - EMEA/H/C/002178/II/0029 Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, “Incresync RMP (version 10.0) includes the following updates: (i) MAH's proposal for removal of aRMMs and consequently the Drug Utilisation Study (DUS) along with removal of relevant commitment (EMEA/H/C/002182/LEG/009). (ii) RMP updated in the new template in order to implement the GVP Module V Revision 2 template along with revising/removal of the safety concerns as summarised below: · The safety concerns for the alogliptin component have been updated. · The safety concerns for the pioglitazone component have been aligned with the consolidated Pioglitazone family RMP (RMP V27.0 as agreed with EMA as part of the worksharing variation procedure [EMEA/H/C/XXXX/WS/1680]). · The safety concerns for alogliptin/pioglitazone FDC have been updated. (iii) Targeted Adverse Event (AE) Follow-up Questionnaires related to AEs of severe hypersensitivity skin reactions, hepatic events, pancreatitis, bladder cancer, malignancies (including pancreatic cancer), bone fractures, and macular oedema were also removed. (iv) RMP has also been updated to reflect the removal of the inverted black triangle as agreed as part of alogliptin renewal procedure (EMEA/H/C/002178/R/0023). Annex II of the PI has been updated accordingly.”
EMA/CHMP/653553/2019 Page 57/67
Orencia - abatacept - EMEA/H/C/000701/II/0134 Bristol-Myers Squibb Pharma EEIG, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, “As a result of the outcome of the Article 46 P64, update of sections 4.8 and 5.1 of the SmPC for Orencia solution for injection in pre-filled syringe based on the final 24-month results from Study IM101301; this is an open-label study to assess pharmacokinetics (PK), safety, and efficacy of SC abatacept in pJIA with no formal hypothesis testing. Update of section 4.8 of the SmPC for Orencia powder for concentrate for solution for infusion based on the final 24-month results from Study IM101301. The package leaflet for Orencia solution for injection in pre-filled syringe has been updated to reflect the removal of the IFU booklet as requested by the CHMP as part of the procedure X/117G. The RMP version 27.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the Annex II and to update Section 4.4 of the SmPC in line with the latest QRD template version 10.1 for all registered presentations. In addition, the list of local representatives in the Package Leaflet has been updated.”
Sancuso - granisetron - EMEA/H/C/002296/II/0056/G Kyowa Kirin Holdings B.V., Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene, “Update of the SmPC section 5.2. to add pharmacokinetic information concluded from a completed paediatric PK study, 392MD/44/C. The RMP has been updated accordingly. The RMP has also been updated to implement RMP template EMA/PRAC/613102/2015 Rev 2 and includes the addition or deletion of safety concerns (identified risks, potential risks, missing information) not previously assessed or requested by a competent authority. The MAH took the opportunity to update the Pregnancy information in section 4.6 of Annex I to align with the QRD statements provided in the QRD product information template. Minor QRD updates have also been made to the English language annex in line with version 10.1 of the QRD template.”
EMA/CHMP/653553/2019 Page 58/67
Zoely - nomegestrol acetate / estradiol - EMEA/H/C/001213/II/0051 Theramex Ireland Limited, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Adrien Inoubli, “To update the RMP to version 9.1, as a result of the outcome of PRAC assessment of the article 107o procedure. The updated RMP includes the reformatting to the new RMP version and several changes including the due date for the PASS study (changed from 30 June 2020 to 30 April 2021). Annex II of the Product Information was updated as a consequence. The MAH also took the opportunity to update the Annex IIIB (Package Leaflet) of the Product Information containing the list of local representatives in the Netherlands and Portugal.”
WS1704 Alimta-EMEA/H/C/000564/WS1704/0058 Pemetrexed Lilly-EMEA/H/C/004114/ WS1704/0010 Eli Lilly Nederland B.V., Lead Rapporteur: Alexandre Moreau, Lead PRAC Rapporteur: Ghania Chamouni, “Worksharing to update section 4.8 of the SmPC as requested by CHMP following the assessment of the PSUR covering the period between 05 February 2015 and 04 February 2018. To comply with SmPC guideline and latest QRD update, the Alimta and Pemetrexed Lilly SmPCs are updated combining multiple tables of ADRs into two tables: one for the ADRs reported in the pivotal registration trials and one for ADRs from the postmarketing period (both clinical trials and spontaneous reporting), organized by SOC with the respective frequency categories. The Package Leaflet is updated accordingly. In addition an updated RMP version 6.1 has been submitted to implement the revised GVP Module V (Rev 2) format as requested by CHMP following the assessment of the PSUR covering the period between 05 February 2015 and 04 February 2018.”
B.6.11. PRAC assessed procedures
PRAC Led BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0033, Orphan Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová,
EMA/CHMP/653553/2019 Page 59/67
PRAC-CHMP liaison: Ondřej Slanař, “Submission of an updated RMP version 11 in line with the guideline on Good Pharmacovigilance Practices (GVP) Module V on RMP. In accordance with the RMP update, the protocol for Category 1 PASS 20150136 has been updated and the enrolment period for the study has been extended by 1 year. The milestones in the RMP were updated accordingly. In addition, the RMP includes a proposed update to the milestone of the Category 3 PASS 20180138.”
PRAC Led Constella - linaclotide - EMEA/H/C/002490/II/0043 Allergan Pharmaceuticals International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “Submission of the final report from study “Linaclotide Utilization Study in Selected European Populations” listed as a category 3 study in the RMP. This is a Drug Utilisation Study (DUS) address following safety concerns - The potential for off-label use and abuse/excessive use - Extent of use in pregnancy and lactation, and male patients - Assess the extent of off-label use and the extent of use in males and in pregnant females”
PRAC Led Darzalex - daratumumab - EMEA/H/C/004077/II/0033, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, “Submission of final study results of a non-interventional PASS to investigate the effectiveness of Darzalex' educational materials concerning the potential risk of daratumumab to interfere with blood typing analysis. This commitment was requested as PAM-001. An updated RMP (v.5.4) to reflect the completion of the study is included in the submission.”
PRAC Led Daxas - roflumilast - EMEA/H/C/001179/II/0038 AstraZeneca AB, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion
EMA/CHMP/653553/2019 Page 60/67
Prieto Yerro, “Amendment of safety concerns and removal of additional risk minimisation measures. Minor changes are implemented in section 4.4 of SmPC and PL according to QRD template.”
PRAC Led Iclusig - ponatinib - EMEA/H/C/002695/II/0053, Orphan Incyte Biosciences Distribution B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Filip Josephson, “Submission of an updated RMP version 20 in order to remove the study AP24534-14-401, a Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With Iclusig (ponatinib) in Routine Clinical Practice in the US (OMNI) from the Pharmacovigilance plan. In addition, in the framework of variation type II/51, it was considered that the distribution of the educational material was not needed anymore. The MAH is therefore also taking the opportunity to amend the RMP to remove reference to these measures.”
PRAC Led Inflectra - infliximab - EMEA/H/C/002778/II/0079 Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of the final clinical study report for C1231002 (PERSIST) study, an observational cohort study designed to evaluate real life drug persistence in biologic naive rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving CT-P13 or those switched to CT-P13 from stable treatment with Remicade (reference medicinal product).”
PRAC Led Inflectra - infliximab - EMEA/H/C/002778/II/0080 Pfizer Europe MA EEIG, Duplicate, Duplicate of Remsima, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of the final clinical study report for C1231001 (CONNECT-IBD) study; a non-interventional study designated as a Post Authorisation Safety
EMA/CHMP/653553/2019 Page 61/67
Study conducted voluntarily to capture data from real-world clinical practice to characterise the population and document drug utilisation patterns. In addition, available safety data and data on the effectiveness of CT-P13 in the context of standard of care utilisation of Remicade (reference medicinal product) was collected in patients with Crohn's disease or ulcerative colitis.”
PRAC Led Instanyl - fentanyl - EMEA/H/C/000959/II/0052 Takeda Pharma A/S, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, PRAC-CHMP liaison: Alexandre Moreau, “Submission of an updated RMP version 19.2 in order to update information relating to educational material.”
PRAC Led Kisplyx - lenvatinib - EMEA/H/C/004224/II/0030 Eisai GmbH, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: David Olsen, PRAC-CHMP liaison: Bjorg Bolstad, “Submission of an updated RMP version 11.3 as a result of interim analysis and updated final report submission dates added for study E7080-G000-307. The protocol for study E7080-G000-307 has been updated to version 06, dated 10 September 2019, to include an interim analysis for profession-free survival and overall survival.”
PRAC Led M-M-RVAXPRO - measles, mumps and rubella vaccine (live) - EMEA/H/C/000604/II/0096 MSD Vaccins, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Submission of an updated RMP (version 4.1) in order to - Align to the new EU RMP template and EMA guideline on good pharmacovigilance practices (GVP) Module V (Rev. 2); - Remove the important potential risk “a potential change in the safety profile related to the replacement of human serum albumin (HAS) with recombinant human albumin (rHA)”; - Remove the missing information related to “exposure during pregnancy”.”
EMA/CHMP/653553/2019 Page 62/67
PRAC Led Mavenclad - cladribine - EMEA/H/C/004230/II/0009 Merck Europe B.V., Rapporteur: Mark Ainsworth, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, “Submission of the final CSR for the PREMIERE registry (EMR700568-012) which is a category 3 study in the RMP. The PREMIERE study is a prospective, observational, long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical studies. It collected long-term safety data from patients previously participating in 1 out of 5 clinical trials (protocol numbers: 25643, 26593, 27820, 27967 and 28821).”
PRAC Led Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0015, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “To update the RMP for Qarziba to version 9.0 to remove from the RMP as missing information Drug-drug interaction, Use in adolescents, adults and elderly, Use in patients with an ethnic origin other than Caucasian, Use in patients with hepatic and renal impairment and Potential harm from overdose.”
PRAC Led Remsima - infliximab - EMEA/H/C/002576/II/0073 Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of the final clinical study report for C1231001 (CONNECT-IBD) study; a non-interventional study designated as a Post Authorisation Safety Study conducted voluntarily to capture data from real-world clinical practice to characterise the population and document drug utilisation patterns. In addition, available safety data and data on the effectiveness of CT-P13 in the context of standard of care utilisation of Remicade (reference medicinal product) was collected in patients with Crohn's disease or ulcerative colitis.”
PRAC Led Remsima - infliximab -
EMA/CHMP/653553/2019 Page 63/67
EMEA/H/C/002576/II/0074 Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola, “Submission of the final clinical study report for C1231002 (PERSIST) study, an observational cohort study designed to evaluate real life drug persistence in biologic naive rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving CT-P13 or those switched to CT-P13 from stable treatment with Remicade (reference medicinal product).”
PRAC Led WS1711 Aluvia-EMEA/H/W/000764/WS1711/0112 Kaletra-EMEA/H/C/000368/WS1711/0181 AbbVie Deutschland GmbH & Co. KG, Lead PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Jean-Michel Race, “To update the RMP for Kaletra and Aluvia (LPV/r) to version 9.0 in order to comply with the current revision 2 of the template. At the same time, the MAH took the opportunity to review the safety information contained in the RMP, removed an important potential risk of drug interaction with telaprevir and boceprevir (HCV protease inhibitors) and missing information regarding use of LPV/r in elderly patients. In addition, the MAH has added information regarding the requirement for a pharmacovigilance (PV) cohort as part of LEG 121 to the RMP.”
B.6.12. CHMP-CAT assessed procedures
Alofisel - darvadstrocel - EMEA/H/C/004258/II/0010/G, Orphan, ATMP Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder
B.6.13. CHMP-PRAC-CAT assessed procedures
B.6.14. PRAC assessed ATMP procedures
B.6.15. Unclassified procedures and worksharing procedures of type I variations
WS1667/G
EMA/CHMP/653553/2019 Page 64/67
Corbilta-EMEA/H/C/002785/WS1667/ 0019/G Levodopa/Carbidopa/Entacapone Orion- EMEA/H/C/002441/WS1667/0028/G Stalevo-EMEA/H/C/000511/WS1667/ 0089/G Orion Corporation, Lead Rapporteur: Outi Mäki-Ikola
WS1684/G Infanrix hexa-EMEA/H/C/000296/ WS1684/0264/G GlaxoSmithkline Biologicals SA, Lead Rapporteur: Bart Van der Schueren
WS1692/G Edistride-EMEA/H/C/004161/WS1692/ 0033/G Forxiga-EMEA/H/C/002322/WS1692/ 0052/G AstraZeneca AB, Lead Rapporteur: Kristina Dunder
WS1694 Infanrix hexa-EMEA/H/C/000296/ WS1694/0265 GlaxoSmithkline Biologicals SA, Lead Rapporteur: Bart Van der Schueren
WS1712 Blitzima-EMEA/H/C/004723/WS1712/ 0028 Ritemvia-EMEA/H/C/004725/WS1712/ 0028 Truxima-EMEA/H/C/004112/WS1712/ 0031 Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz
WS1734 Riarify-EMEA/H/C/004836/WS1734/0005 Trimbow-EMEA/H/C/004257/WS1734/ 0010 Trydonis-EMEA/H/C/004702/WS1734/ 0005 Chiesi Farmaceutici S.p.A., Lead Rapporteur: Janet Koenig, “To provide an updated Enviromental Risk Assessment (ERA) report.”
WS1739 Fluenz Tetra-EMEA/H/C/002617/WS1739/ 0096 Pandemic influenza vaccine H5N1
EMA/CHMP/653553/2019 Page 65/67
AstraZeneca-EMEA/H/C/003963/WS1739/ 0030 AstraZeneca AB, Lead Rapporteur: Bart Van der Schueren
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY
B.7.1. Yearly Line listing for Type I and II variations
B.7.2. Monthly Line listing for Type I variations
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)
B.7.6. Notifications of Type I Variations (MMD only)
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)
E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES
Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.
E.1. PMF Certification Dossiers:
E.1.1. Annual Update
E.1.2. Variations:
E.1.3. Initial PMF Certification:
E.2. Time Tables – starting & ongoing procedures: For information
PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).
EMA/CHMP/653553/2019 Page 66/67
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver
F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health
G. ANNEX G
G.1. Final Scientific Advice (Reports and Scientific Advice letters):
Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.
G.2. Ongoing procedures
G.3. PRIME
Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.
G.3.1. List of procedures concluding at 14-17 October 2019 CHMP plenary:
Oncology 1. MB-CART2019.1 ATMP; Treatment of The CHMP granted eligibility to PRIME and patients with relapsed and refractory adopted the critical summary report. diffuse large B-cell lymphoma (DLBCL) after frontline therapy and who are ineligible for autologous stem cell transplantation 2. Treatment of patients with The CHMP denied eligibility to PRIME and previously-treated non-small cell lung adopted the critical summary report. cancer Endocrinology-Gynaecology-Fertility-Metabolism 3. Teplizumab SME; Treatment to delay or The CHMP granted eligibility to PRIME and prevent clinical Type 1 diabetes in “at-risk” adopted the critical summary report. individuals Haematology-haemostaseology 4. BAY2599023 ATMP; Treatment of The CHMP granted eligibility to PRIME and haemophilia A adopted the critical summary report. Neurology 5. Disease modifying treatment for mild The CHMP denied eligibility to PRIME and cognitive impairment (MCI) due to adopted the critical summary report. Alzheimer’s disease (AD) and mild AD dementia Immunology-Rheumatology-Transplantation 6. SME; Prevention of graft versus host The CHMP denied eligibility to PRIME and disease adopted the critical summary report.
G.3.2. List of procedures starting in October 2019 for November 2019 CHMP adoption of outcomes
H. ANNEX H - Product Shared Mailboxes – e-mail address
EMA/CHMP/653553/2019 Page 67/67